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ABSTRACT  
The metabolic syndrome (MetS) is an established risk factor cluster for cardiovascular disease 
(CVD) and type 2 diabetes (T2DM). A rapid increase in the prevalence of obesity worldwide is 
also associated with an increase of  the MetS. Abdominal obesity and insulin resistance are 
probably the key elements of the syndrome. The role of low-grade inflammation and 
hypoadiponectinemia remains unclear in the MetS. 
   The aim of this study was to evaluate the association and significance of low-grade 
inflammation, measured by high-sensitivity(hs)-CRP and IL-1 receptor antagonist (IL-1 Ra), and 
adiponectin with the MetS in a population-based study. 
   The study population consisted of subjects from five different age groups (mean age 46 years) 
living in the city of Pieksämäki. Altogether 923 of 1 294 (71.3%) individuals participated in the 
cross-sectional studies in 1997-98. The prevalence of the MetS according to the International 
Diabetes Federation (IDF) definition was 38% in men and  34% in women. The corresponding 
figures according to the National Cholesterol Education Program (NCEP) definition were 34% 
and 27%. 
   The levels of pro-inflammatory markers, hs-CRP and IL-1 Ra, were significantly higher among 
women with the MetS compared to men with the MetS, independently of the definition used. In 
contrast, no gender difference in these markers between men and women was observed in 
subjects without the MetS. 
   The relative change in BMI from childhood to adulthood and the levels of adiponectin and 
markers of a low-grade inflammation were related. The association was particularly strong 
among women. Insulin sensitivity correlated significantly with adiponectin and IL-1 Ra levels, 
independently of confounding factors, but did not correlate with hs-CRP. The levels of 
adiponectin, hs-CRP and IL-1 Ra were similarly and linearly correlated with the number of 
components of the MetS in both sexes according to the IDF and NCEP definitions.     
   In conclusion, the MetS was associated with hypoadiponectinemia and low-grade 
inflammation measured by hs-CRP and IL-1 Ra in this cross-sectional population-based study. 
An association was found between the relative change in BMI between childhood and 
adulthood, insulin sensitivity, the number of components of the MetS and, above all, female 
gender. Low-grade inflammation could be one explanation why prediabetic women tend to have 
a more atherogenic risk profile than males years before the diagnosis of diabetes. This long-
lasting inflammatory stress may in part explain why T2DM is related to relatively higher CVD 
mortality in women than in men. 
 
National Library of Medicine Classification: WB 286, WD 210, WD 200.5.H8, WG 120, WK 810 
Medical Subject Headings: Adiponectin; Adult; Body Mass Index; C-Reactive Protein; Cross-
Sectional Studies; Diabetes Mellitus, Type 2; Cardiovascular Diseases; Child; Female; Finland; 
Humans; Inflammation; Insulin Resistance; Interleukin 1 Receptor Antagonist Protein; Male; 
Metabolic Syndrome X; Obesity; Risk Factors 
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1. INTRODUCTION 
 
 
The metabolic syndrome (MetS)  is the clustering of multiple cardiovascular risk factors in an 
individual. The constellation of metabolic abnormalities includes glucose intolerance (type 2 
diabetes, impaired glucose tolerance, or impaired fasting glycemia), insulin resistance, central 
obesity, dyslipidemia, and hypertension, all well-documented risk factors for CVD. These 
conditions co-occur in an individual more often than  expected by chance and are associated 
with increased risk for cardiovascular disease (CVD) (1,2) and type 2 diabetes mellitus (T2DM) 
(3,4). 
   Over the past two decades, there has been a striking increase in the number of people with 
the MetS worldwide. This increase is associated with a global epidemic of obesity and diabetes 
(5), and the syndrome is seen more often in young adults and children (6).   
    The pathophysiology of the MetS is complex and not completely understood.The detrimental 
effects of visceral adipose tissue accumulation and the active endocrine role of adipose tissue 
have been ackowledged  in recent years. Abdominal obesity is believed to be the cause for the 
MetS, as it clusters with diabetogenic, atherogenic, prothrombotic and proinflammatory 
metabolic abnormalities (7). Adipose tissue secretes a variety of bioactive substances called 
adipocytokines, which are closely linked to the MetS and its complications (8). A recently 
discovered protein, adiponectin, is the most abundant adipocytokine (9), and its expression is 
highly specific to adipose tissue. Adiponectin has insulin-sensitising properties (10). Reduced 
adiponectin levels are observed in viscerally obese subjects which contribute to an atherogenic 
and diabetogenic metabolic risk factor profile (11). In obesity, there is evidence of macrophage 
infiltration in adipose tissue, leading to an inflammatory condition characterised by elevation of  
the Interleukin (IL) cytokine superfamily, tumour necrosis factor-Į (TNF- Į) and C-reactive 
protein (CRP). Adipose tissue produces, presumably as an adaptive response to chronic stress, 
anti-inflammatory factors suchs as interleukin-1 receptor antagonist (IL-1 Ra) (12). Insulin 
resistance is increasingly recognized as a chronic, low-grade, inflammatory state. 
Atherosclerosis and insulin resistance share similar pathophysiogical mechanisms. This low-
grade inflammation could be the link between T2DM and atherosclerosis ("common soil 
hypothesis") (13).Thus, understanding of the pathophysiology of the MetS and identification of 
subjects with MetS is highly important. There is urgent need for effective strategies to prevent 
this emerging global epidemic to be able to prevent the increase of CVD and T2DM (5). 
   In this population-based study  the association and the role of adiponectin, CRP and IL-1 Ra 
applying two different definitions of the MetS were examined. The association of the above-
mentioned proinflammatory markers and adiponectin were also analyzed with relative change in 
BMI between childhood and adulthood, insulin sensitivity and gender differences in the 
15
prevalence of the MetS in a cohort of 5 age groups born in 1942, 1947, 1952, 1957 and 1962 ( 
N=1294) in the town of Pieksämäki (population about 20 000), in eastern Finland. 
    The review of literature will discuss the evolution of the concept, different definitions, 
epidemiology, and the closely related components of the MetS, especially low-grade 
inflammation and hypoadiponectinemia. The genetics, lifestyle factors, treatment, early life 
aspects and gender differences with the MetS will also be discussed.  
 
 2. REVIEW OF LITERATURE  
 
2.1. Metabolic syndrome 
 
2.1.1. Evolution of the concept of the metabolic syndrome 
 
Some 250 years ago in the 18 th century Joannes Baptista Morgagni introduced the 
mechanistic concept in human physiology and pathology. With the help of only knife for 
anatomical dissection he was able to identify the intra-abdominal and mediastinal fat 
accumulation in android obesity. He described the association between visceral obesity, 
hypertension, hyperuricemia, atherosclerosis and obstructive sleep apnea (14). In modern 
medical literature the same clustering of cardiovascular risk factors, hypertension, 
hyperglycemia and hyperurikemia, was first described in 1923 by Kylin, a Swedish physician 
(15). Later, in 1947, the French physician, Vague, drew attention to upper body adiposity 
(android or male type obesity) as the obesity phenotype that was often associated with 
metabolic abnormalities, diabetes and cardiovascular disease (16).  
   In his Banting Lecture professor Gerald Reaven in 1988 described "Syndrome X" (17). This 
syndrome was "a cluster of risk factors for diabetes and cardiovascular disease" and tightly 
associated with insulin resistance. Subsequently, the MetS was called " the deadly quartet"(18) 
or "the insulin resistance syndrome" (19). However, the etiology of the syndrome has remained 
unclear. In 1998, the World Health Organization (WHO) proposed the first internationally 
accepted criteria for the MetS (20). The term “metabolic syndrome” was preferred over “insulin 
resistance syndrome”(Figure 1).  
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Figure 1. The classical features of metabolic syndrome. Insulin resistance and hyperinsulinemia 
are the core of the syndrome. Central obesity may also have an etiological role. Dysplipidemia, 
elevated blood pressure and glucose intolerance are included in the criteria and  they might 
result  from the underlying insulin resistance. 
 
2.1.2. Definitions of the metabolic sydrome  
 
Despite general recognition of the syndrome, the lack of knowledge of its etiology and uniform 
diagnostic criteria complicated  epidemiological studies of the MetS  for many years. The WHO 
diagnostic criteria  was the first attempt to achieve some agreement on the definition, 
particularly for research purposes (20). Insulin resistance was the primary abnormality of this 
diagnosis. It had to be coupled with any two other features of the syndrome (central obesity, 
elevated blood pressure, dyslipidemia and microalbuminuria). The report clearly stated that the 
definition did not imply causal relationships and that the definition could he modified as new 
information was gathered. 
   The WHO criteria have been criticized because of the inclusion of microalbuminuria as a 
component of the syndrome. Microalbuminuria in non-diabetic individuals is uncommon (21) 
and its association with other components of the syndrome is not consistent (22,23). 
Furthermore, the requirement that insulin resistance should be measured with the 
hyperinsulinemic euglycemic clamp technique (24) in glucose tolerant subjects made the criteria 
Insulin Resistance
 
 
 
Hyperinsulinemia 
(Central) 
Obesity 
Elevated 
blood 
pressure 
Glucose 
Intolerance
Dyslipidemia 
TG /  HDL 
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impractical for epidemiological studies. For these reasons the European Group for the Study of 
Insulin Resistance (EGIR) presented a simpler definition, particularly for epidemiological studies 
(25). Insulin resistance was still the central element of the diagnosis, but it was defined as the 
presence of fasting hyperinsulinemia (25,26). Other differences compared to the WHO criteria 
were the cut-off points for hypertension and dyslipidemia (Table 1). Furthermore, instead of the 
waist-to-hip ratio (WHR), waist circumference was proposed as a measure of abdominal obesity 
because it showed a stronger correlation with intra-abdominal adipose tissue mass (27). 
Microalbuminuria was not included in the EGIR criteria. 
   The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) published their 
diagnostic criteria for the MetS in 2001 (28). This definition was based on fasting triglycerides, 
high-density lipoprotein (HDL) cholesterol, plasma glucose, waist circumference and blood 
pressure with equal weight on each component. Insulin resistance was not included in the 
definition of the syndrome. American Association of Clinical Endocrinologists (AACE) published 
their slightly different modified NCEP criteria in 2002 to refocus on insulin resistance as the 
primary cause of metabolic risk factors. Like the EGIR, they used the name insulin resistance 
syndrome. Major criteria were IGT, elevated triglycerides, reduced HDL cholesterol, elevated 
blood pressure, and obesity. No specified number of factors qualified for diagnosis, which was 
left to clinical judgment (29). 
   Recently, the International Diabetes Federation (IDF) revised the definition of the MetS (30) to 
be globally more useful. In the IDF criteria abdominal obesity is recognized as an underlying 
factor for the syndrome. Therefore, a large waist circumference was defined as a compulsatory 
component for the diagnosis of the MetS. For the first time ethnic-specific cut-points for waist 
circumference were given. For Caucasian men the cut-off point is  94 cm and for European 
women 80 cm, based on the sensitivity and specificity of these cut-off points to identify 
subjects with body mass index (BMI) >25 kg/ m2 or WHR t0.9 for men and t0.85 for women 
(31). The cut-off points for waist circumference for Asian populations are lower since their risk 
for T2DM and CVD is apparent at lower levels of adiposity than in Europeans (32). The criteria 
for dyslipidemia and elevated blood pressure are identical to those of the NCEP definition, but 
the limit for hyperglycemia has been lowered to t 5.6 mmol/1 according to the new definition of 
impaired fasting glucose by the American Diabetes Association (ADA) (33).  
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2.1.3. Epidemiology of the metabolic syndrome  
 
2.1.3.1. Prevalence of the metabolic sydrome 
 
The prevalence and consequences of the MetS were difficult to estimate before more generally 
accepted definitions of the syndrome were published. It has become obvious that 
simultaneously with an increase in obesity there has been an increase in the prevalence of the 
MetS. Analysis of data on a representative sample of 8814 men and women in the United 
States (Third National Health and Nutrition Examination Survey from 1988-1999), estimated that 
the age-adjusted prevalence of the MetS according to the NCEP criteria was 23.6% (35). The 
prevalence of the MetS increased from 6.7% among  participants aged from 20 to 29 years to 
43.5% for participants aged from 60 to 69 years. There were also considerable differences in 
the prevalence of MetS among different ethnic groups (35). The prevalence was highest among 
Mexican Americans (31.9%) and lowest among Caucasians (21.6%), African Americans 
(21.6%) and people reporting "another" race or ethnicity (20.3%). Comparison of the WHO and 
the NCEP definitions showed that the age-adjusted prevalence of the MetS was quite similar, 
25.1% and 23.9%, respectively, but 15-20% of  the individuals were classified as having the 
syndrome based on one definition but not on the other, with equal discordance (36). 
   In a Finnish study of 1 209 middle-aged men (42-60 years) the prevalence of MetS in 1984-
1989 was 14.2%, according to the WHO (insulin resistance estimated as hyperinsulinemia), and  
8.8 % according to the NCEP definitions. The prevalence numbers are rather low, but subjects 
with diabetes and CVD were excluded from this cohort (2). More recent data from Finland show 
that according to the modified WHO criteria, the prevalence numbers in the 1992 FINRISK 
survey, conducted as part of the FINMONICA cardiovascular risk factor study, were much 
higher in men (38.8 %) and in women (22.2 %). The prevalence rates were also analyzed  in 
different categories of glucose tolerance in this cross-sectional, population-based sample of 2 
049 individuals. The prevalence of the MetS was 14.4% in  men and 10.1% in women with 
normal glucose tolerance (NGT), 84.8% and 65.4% among those with impaired glucose 
tolerance (IGT) and 91.1% and 82.7% in subjects with type 2 diabetes, respectively (37). In the 
same publication, the Finnish Diabetes Prevention Study (DPS) cohort was analyzed and the 
prevalence of the MetS in 522 participants with IGT was 78.4% for men, and 72.2% for women 
(37). 
    The prevalence of the MetS in a random sample of 207 middle-aged subjects in Tampere 
and 1 148 subjects in Pieksämäki in 1993-94 were 17% in men and 8% in women. In this study 
the MetS was defined as a clustering of dyslipidemia (hypertriglyceridemia, low HDL cholesterol 
or both) and insulin  resistance (abnormal glucose tolerance, hyperinsulinemia, or both) (38,39). 
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Recent data on 1 099 healthy Finnish male military conscripts around 19 years of age showed 
prevalence numbers of the MetS to be 6.8% according to the IDF and 3.5% by the NCEP (40). 
   A recent study of 9 669 subjects representative of the Greek  population reported a 
prevalence of the MetS 24.5% according to the NCEP criteria, which is very similar to the 
prevalence in US and Finnish adults (41). According to the new IDF definition, the age-adjusted 
prevalence of the MetS in the same Greek population was 43.4% and thus much higher. The 
significantly higher prevalence of the MetS by the IDF definition was attributable to the lower 
cut-off points for waist circumference and fasting glucose since most subjects with only one or 
two NCEP diagnostic criteria had the MetS according to the IDF definition (41). 
   Little is known about  the prevalence of the MetS among children and adolescents. Data from 
the U.S. on adolescents aged 12-17 years in 1999-2004 showed that the prevalence of the 
MetS using the  IDF definition was about 4.5%. It increased with age, was higher among males 
(6.7%) than females (2.1%), and was highest among Mexican-Ameican adolescents (7.1%) 
(42). These figures are possibly higher nowadays, because of the rapid rise in adiposity among 
youth. 
 
2.1.3.2. Metabolic syndrome and the risk of cardiovascular disease and type 2 diabetes 
 
The main reason for identifying subjects with the metabolic syndrome is the fact that these 
individuals are at a high risk for developing CVD and T2DM (43). 
    Several prospective population-based studies have investigated the association between 
metabolic risk factors and CVD. In a large cohort of about 20 000 men and women, followed for 
an average of 7 years, the all-cause and CVD mortality increased  with  increasing number of 
abnormalities associated with the MetS (44).  
   In the Helsinki policemen study cohort, the insulin resistance factor during the 22-year follow-
up had an age-adjusted hazard ratio of 1.28 for CVD risk and 1.64 for stroke risk. In the same 
study the lipid factor predicted the risk of CVD, but not that of stroke (45). The MetS also 
predicted  coronary heart disease events in elderly (65-74 years) non-diabetic Finnish men 
followed up for 7 years (hazard ratio 1.33) (46).  
   In the Botnia study 4 483 subjects aged 35-70 years were evaluated for cardiovascular risk 
associated with the MetS applying the WHO definition (insulin resistance estimated by HOMA). 
The prevalence of CHD and stroke was 3-fold higher  in subjects with the syndrome and their 
mortality markedly increased (12.0%) during the 7-year prospective follow-up compared to 
subjects without the syndrome (2.2%) (1). 
   In the Kuopio Ischaemic Heart Disease Risk Factor Study,  a population-based, prospective 
cohort study of 1 209 Finnish men aged 42 to 60 years at baseline (1984-1989) who were 
initially without CVD, cancer, or diabetes were followed up until December 1998. Those with the 
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MetS defined applying the NCEP criteria (waist > 102 cm) had 4.2  times and those with the 
MetS defined by the other NCEP criteria (waist > 94 cm) 2.9 times higher risk to death from 
CHD than men without the MetS after  adjustment for conventional cardiovascular risk factors. 
The corresponding figures, according to the WHO definition of the MetS were from 2.9 (waist-
hip ratio >0.90 or BMI  30) to 3.3 (waist  94cm) (2).  
   The predictive value of the WHO and NCEP criteria were compared in the San Antonio Heart 
Study (2 815 subjects aged 25-64 years, average follow-up time 12.7 years), where the 
prevalence rate of the MetS in the general population was 25.2% using both definitions. In the 
general population the NCEP criteria were predictive of all-cause mortality (hazard ratio 1.5) 
and CVD mortality (hazard ratio 2.5).The WHO criteria only predicted CVD mortality (hazard 
ratio 1.6) (47). 
   The Hoorn Study comprised 615 men and 749 women aged 50 to 75 years without diabetes 
and a history of CVD at baseline in 1989-1990. The prevalence of the MetS ranged from 17-
32% using different definitions (NCEP,WHO, EGIR). All the definitions  increased the risk for 
incident cardiovascular morbidity and mortality in 10 years about 2-fold (48). 
    In the ARIC study population men and women fulfilling the NCEP definition of the MetS had a 
1.5 to 2 times higher risk for developing CHD or stroke after adjustments, but having the MetS 
did not improve CHD risk prediction beyond the level achieved by the Framingham Risk Score 
(49). In contrast in the Scandinavian Simvastatin Survival Study(4S) and Air Force/Texas 
Coronary Aterosclerosis Prevention Study (AFCAPS/TexCAPS) placebo-treated patients with 
MetS defined by the NCEP criteria showed increased risk for major coronary events irrespective 
of their Framingham-calculated 10-year-risk score category (50). 
   In a prospective 4-year follow-up study of 750 coronary patients who underwent coronary 
angiography, the NCEP-definition of the MetS conferred a significantly higher risk for vascular 
events than the IDF definition (51). The MetS, as defined by all the main criteria, also predicted 
incident end-stage peripherial vascular disease (PVD) in a prospective population based study 
in the elderly, but only when adjusted for diabetes status. Two of the single components of the 
MetS, elevated fasting plasma glucose and microalbumiuria, predicted PVD (52). 
   The other major complication of the MetS is T2DM (3,4). Overall, the risk for type 2 diabetes 
in patients with the MetS is 3-5-fold higher (53). In the Insulin Resistance Atherosclerosis Study 
the IDF and NCEP definitions were shown to predict type 2 diabetes equally well (54). A close 
relationship between the MetS and glucose tolerance was demonstrated in the Botnia study, 
where the prevalence of the MetS was 10% in women and 15% in men with normal glucose 
tolerance compared to 42 and 62% in subjects with impaired glucose tolerance (IGT) and 78 
and 84% in subjects with T2DM (1).The predictive power of the MetS for incident diabetes in a 
Chinese high-risk population was tested during a 5-year follow-up.The NCEP, WHO, EGIR and 
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AACE  definitions identified men as having a 3,7-4.5-fold and women a 1.6-2.8-fold risk of 
developing diabetes during the 5-year follow-up (55).  
   Finally, in the San Antonio Heart Study, the WHO, NCEP and IDF definitions showed a similar 
ability to predict incident diabetes, which ability was not fully explained by glucose intolerance. 
All definitions predicted incident diabetes independently of age, sex, ethnic origin or family 
history of diabetes (56). 
 
2.1.4. Inflammation and metabolic disorders 
 
The metabolic and immune systems are among the most fundamental requirements for survival. 
Many metabolic and immune response pathways or nutrient-pathogen-sensing systems have 
been evolutionarily conserved throughout species. As a result, immune response and metabolic 
regulation are highly integrated and the proper function of each is dependent on the other. This 
interface can be viewed as a central homeostatic mechanism, dysfunction of which can lead to 
a cluster of chronic metabolic disorders, particularly obesity, type 2 diabetes and cardiovascular 
disease (57). 
   The finding in 1993 that tumour necrosis factor-Į (TNF- Į) is overexpressed in the adipose 
tissue of obese mice provided the first clear link between obesity, diabetes and chronic 
inflammation (58). With regard to inflammation, the traditional features of this state do not apply 
to the diseases in question. In the classic literature, inflammation is described as the principal 
response of the body invoked to deal with injuries, the hallmarks of which include swelling, 
redness, pain and fever (tumor,  rubor, dolor and calor) (59). This, often short-term, adaptive 
response is a crucial component of tissue repair and involves the integration of many complex 
signals in distinct cells and organs. However, the long-term consequences of prolonged 
inflammation are often not beneficial. Although many of the same mediators are involved in 
obesity and diabetes, few, if any, of the classic features of inflammation have been observed. 
Therefore, this new distinct form of injury response is called low-grade or chronic 
inflammation.This condition is principally triggered by nutrients and metabolic surplus, and 
engages a similar set of molecules and signalling pathways to those involved in classical 
inflammation (57). 
   Both adipose tissue and the liver have an architectual organization in which metabolic cells 
(adipocytes or hepatocytes) are in close proximity to immune cells (Kupffer cells or 
macrophages) and both have immediate access to a vast network of blood vessels. This 
interface might contribute to the emerging importance of these two organs in the initiation and 
development of metabolic diseases, particularly in the context of obesity and type 2 diabetes. 
This chronic inflammation is characterized by abnormal cytokine production, increased acute-
23
phase reactants and other mediators, and activation of a network of inflammatory signalling 
pathways (60,61). 
 
2.1.5. Future challenges for diagnostics and definition 
 
Although the diagnosis of the MetS has been established and accepted by international 
organizations, the reasons for using the diagnosis have recently been questioned (63). 
Diagnosis is warranted if a syndrome reflects a unifying pathological process or predicts future 
adverse event(s) better than the sum of its components. According to its critics, the current data 
on the MetS does not fulfill either of these criteria,  and thus the labeling of subjects with the 
term MetS shoud be avoided. In their critical joint statement the American Diabetes Association 
(ADA) and the European Association for the Study of Diabetes (EASD) expressed  concerns 
regarding the MetS that the criteria are ambiguous or incomplete and the rationale for 
thresholds are ill defined. The value of including diabetes in the definition is questionable and 
insulin resistance as the unifying etiology is uncertain. It is stated  that there is no clear basis for 
excluding other CVD risk factors as smoking and elevated LDL cholesterol, and therefore the 
CVD risk associated with the syndrome appears to be no greater than the sum of its parts. The 
treatment of the syndrome is not different from the treatment of each of its components (62).  
   Furthermore, the separate components of the syndrome may show different risk profiles 
(49,63,64), suggesting that the different combinations do not carry equal risk. According to a 
recent review by Richard Kahn, entitled  “ The metabolic syndrome (emperor) wears no 
clothes”, the dichotomous nature of the diagnosis of the MetS is problematic, because the 
criteria included in the definition are continuous variables with no upper limits given for any of 
them (65). 
   The high intercorrelation between the components of the MetS complicates the use of 
traditional statistical methods and therefore, confirmatory factor analysis, a multivariate 
correlation method, has been used to investigate the relationship of the variables included in the 
syndrome (66,67). Factor analysis identifies statistically independent latent factors underlying 
the associations of the included variables. If an analysis reveals only a single factor this 
supports the hypothesis that the MetS has a common etiology e.g. insulin resistance. The other 
case is that several factors represent distinct physiological phenotypes, which suggests a more 
complex etiology. However, if a variable is associated with more than one factor, this overlap 
indicates unifying commonalities between physiological domains and  provides an insight into 
the common factor underlying the syndrome (66). Factor analysis has consistently yielded from 
2 to 4 factors for the MetS with a separate obesity-hyperinsulinemia factor (46,68-72) that in 
many cases also included dyslipidemia. Blood pressure has most consistently loaded on a 
separate factor (68,69,71,72). 
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   Confirmatory factor analysis supports the current clinical definition of the MetS, as well as the 
existance of a single factor that links all of the core components (73). The same one factor 
model was found also in adolescents and the model appeared to be consistent across sex and 
racial/ethnic subgroups (74). Further investigation is needed to determine whether the core 
factor is genetic or enviromental (73). 
2.2. Etiology and components of the metabolic syndrome 
 
The original description of the MetS was based on the assumption that the syndrome is a 
clinical manifestation of insulin resistance. However, it is unlikely that insulin resistance can 
explain all the components of the MetS. As more data have been published and many new 
features have been proposed as being part of the syndrome (low-grade inflammation, 
hypoadiponectinemia, endothelial dysfunction and prothrombotic state), abdominal obesity has 
been nominated as a marker of “ dysfunctional adipose tissue”, and is of central importance in 
the clinical diagnosis of the MetS (7). Also environmental, possibly preventive, intrauterine and 
early life factors are involved along with genetics in the pathophysiology of the MetS (Figure 2). 
 
Figure 2. Components of the metabolic syndrome. Diet, genes and physical inactivity contribute 
to the pathophysiology of the MetS. 
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2.2.1. Abdominal obesity and fat distribution 
 
The dramatic worldwide increase in the prevalence of obesity, defined as BMI > 30 kg/m², is the 
most important underlying cause for the increasing prevalence of the MetS and T2DM (5). 
Basically, obesity results  from an imbalance between energy intake and energy expenditure. 
However, this balance is modified by numerous genetic, environmental and psychososial 
factors (75). In 1956, Vaque reported for the first time  that android-type upper body fat 
deposition is associated with increased risk for chronic diseases, including diabetes, 
atherosclerosis and gout (76). 
   In the NHANES study conducted in the U.S between 1989 and 1994 according to the NCEP 
criteria 30.1% of  men had abdominal obesity, while 5 years later  it had increased to 36.0%. A 
similar increase was observed in women during the same period from 45.7% to 51.9% (77). In a 
recent Finnish population-based study of 45 to 65-year old persons, the prevalence of 
abdominal obesity was 68.8% in men and 76.4 % in women, according to the IDF criteria ( 94 
cm for men and  80 cm for women), and 36.4% and 51.8%, according to the NCEP criteria 
(102 for men and 88 cm for women) (78). 
   Randomly chosen primary care physicians in 63 countries recruited consecutive patients aged 
18 to 80 years on 2 prespecified half days. Waist circumference and BMI were measured and 
the presence of CVD and diabetes mellitus recorded. Overall, 24% of 69 409 men and 27% of 
98 750 women were obese (BMI > 30 kg/m²). A further 40% and 30 % of men and women, 
respectively, were overweight. Increased waist circumference (>102 cm for men and > 88 cm 
for women) was noted in 29% and 48%, CVD in 16% and 13%, and diabetes mellitus in 13% 
and 11% of men and women, respectively. A statistically significant graded increase existed in 
the frequency of CVD and diabetes mellitus for both BMI and waist (79). 
   While BMI provides an indicator of overall obesity for epidemiological purposes, a more 
accurate assessment of total body composition can be obtained by bioelectrical impedance 
(80), underwater weighing (81) or dual energy X-ray absorptiometry (DEXA) (82). Waist 
circumference is probably the most important anthropometric measure, because the impact of 
the distribution of body fat is crucial for the metabolic consequences. Waist circumference 
correlates with abdominal obesity better than waist-to-hip ratio (WHR) (28). The most reliable 
assessment of abdominal fat distribution can be obtained with computed tomography (83) or 
magnetic resonance imaging (84). 
   Adipose tissue is distributed throughout the body as large homogeneous discrete 
compartments and as small numbers of cells "marbling" or adjacent to other tissues. Most 
adipose tissue (about 85% of total adipose tissue mass) is located under the skin 
(subcutaneous fat) in both lean and obese persons (85). In both sexes, older men and women 
had a significantly greater increase in visceral fat measured by MRI for a given waist 
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circumference than  younger men and women (< 50 years) (86). The term "visceral fat" is 
commonly used to describe intra-abdominal fat, and includes both intraperitoneal fat 
(mesenteric and omental fat), which drains directly into portal circulation, and retroperitoneal fat, 
which drains into the systemic circulation. The relative contribution of intra-abdominal fat mass 
to total body fat is influenced by sex, age, race/ethnicity, physical activity, and total adiposity 
(87). At any given level of waist circumference, the prevalence of diabetes is consistently higher 
in Asians than in Caucasians (88,89). 
    Since Vaque's work a large number of both cross-sectional and prospective studies have 
assessed the impact of body fat distribution and confirmed the link of abdominal obesity with 
insulin resistance (90,91), the metabolic syndrome (92,93), T2DM (94,95), CVD (96,97) and 
mortality independently of BMI (98). An increase in visceral fat mass, despite similar total fat 
mass, has been demonstated in subjects with family history of T2DM compared with subjects 
without. This  suggests that increased visceral fat mass may be an early sign of predisposition 
to the development of insulin resistance and T2DM (99). 
   In addition to its function as a store of surplus energy, adipose tissue has multiple regulatory 
functions in metabolism. Changes in biological properties of adipocytes are thought to 
contribute to the adverse metabolic effects of abdominal fat tissue. In the normal state the 
balance between adipose tissue, lipolysis and triglyceride synthesis is carefully governed by 
energy status, various hormones and the autonomic nervous system. This balance is disrupted 
in abdominal obesity due to an increase in both fasting and postprandial free fatty acid (FFA) 
levels (100,101). Furthermore, visceral adipose tissue has been shown to be more sensitive to 
ȕ-adrenergic lipolysis than subcutaneous adipose tissue because of the larger numbers of ȕ-
adrenergic receptors on the cell surface (102). The antilipolytic effect of insulin has shown to be 
impaired in visceral adipose tissue, resulting in an excess supply of FFAs and causing multiple 
adverse events closely associated with insulin resistance (103,104). Viscerally obese subjects  
are also characterized by an exaggerated postprandial triglyceride response (105,106). 
   However, it is not known whether the storage of an absolute or relative excess amount of 
triglycerides in abdominal fat depots is directly responsible for increased disease risk or whether 
such deposition is simply associated with other processes that cause risk (87). In one of the 
earliest hypotheses, Björntorp proposed that intra-abdominal fat mass was the result of 
activation of the hypothalamic-hypopituitary-adrenal axis by environmental stress (107-109). 
More recently, it has been suggested that the limited ability of subcutaneous fat depots to store 
excess energy results in "overflow" of chemical energy to intra-abdominal fat tissue and"ectopic" 
sites, causing insulin resistance in the liver (110) and skeletal muscle (111), whereas fat 
accumulation in the liver rather than in skeletal muscle is associated more with features of the 
MetS (112). Liver fat content has been found to be 4-fold higher in subjects with the MetS than 
without, independently of age, gender, or body mass index (113), and  type 2 diabetic patients 
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have 80% more liver fat, underestimated by ALT level, than age-, weight-, and gender-matched 
non-diabetic subjects (114). Even in obese adolescents high visceral and low abdominal 
subcutaneous fat stores, measured in many different ways are the main determinants of an 
adverse metabolic phenotype (115). 
    The biological activity of an adipocyte changes as its lipid storage increases. Compared with 
small adipocytes, large cells are more insulin-resistant and lipolytic, release more inflammatory 
cytokines and less adiponectin (116,117), and are more frequently found in people with obesity-
related metabolic disorders (118). 
   These hypotheses are not mutually exclusive, and it is possible that all, including genetic 
factors, are involved in the association between abdominal fat mass and adverse metabolic 
consequences.  
2.2.1.1. Adipokines secreted by adipose tissue  
 
Adipose tissue is not only involved in the storage and mobilization of lipids but is also an 
important endocrine organ releasing numerous polypeptides, collectively termed adipokines.The 
term adipokine is generally applied to biologically active substances found in the adipocytes of 
adipose tissue (119). Adipokines include a variety of proinflammatory peptides: TNF-Į, 
Interleukin(IL)-6, CRP, adiponectin, leptin, resistin, visfatin, PAI-1, apelin, hepcidin, vaspin and  
IL-1 Ra (120) (Table 2). 
   TNF-Į is a paracrine mediator in adipocytes and appears to act locally to reduce insulin 
sensitivity of adipocytes (121). This leads to high release of FFA:s and atherogenic dyslipidemia 
(122). TNF-Į also increases the secretion of other inflammatory mediators (121). 
    IL-6 is a systemic adipokine, which not only impairs insulin sensitivity, but is also a major 
determinant of  the hepatic production of C-reactive protein (CRP), the most important source of 
this inflammatory marker (123). The role of CRP in the MetS is discussed later in section 
2.2.5.2. During the last decade, an accumulating amount of data  has suggested that IL-6 plays 
a pivotal role as a multifaceted pleiotropic cytokine.  IL-6 produced in the working muscle during 
physical activity could act as an energy sensor by activating AMP-activated kinase and 
enhancing glucose disposal, lipolysis and fat oxidation (124). 
   Adiponectin is the most abundant adipokine in the plasma (125). In contrast to other 
adipokines, adiponectin level is inversely associated with insulin resistance, obesity, the MetS 
and type 2 diabetes (8,126), and women have higher levels of adiponectin compared to men 
(127). The role of adiponectin is discussed later in section 2.2.5.1. 
   Leptin was first identified in 1994 as a hormone secreted by adipocytes. It is a 16 kDa non-
glycosylated peptide hormone encoded by the gene obes(ob), the murine homolog of the 
human gene LEP (128). Adipose tissue is the only known source of leptin, and its secretion is 
proportional to adipocyte size (129). Leptin participates in the regulation of appetite and energy 
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expenditure (130), acts as a potential modulator of the hypothalamic-pituitary-adrenal-axis 
(131), and is considered a hormone with pleiotropic actions (132). Leptin acts as a fundamental 
signal for the brain to modulate food intake as a function of energy status. Loss of leptin function 
results in obesity (133). In men (134) and patients with type 2 diabetes (135), plasma leptin 
levels are associated with the occurrence of cardiovascular diseases. Because the level of 
leptin increases with obesity and that of adiponectin decreases with obesity, the ratio of leptin to 
adiponectin can be used as an index of insulin resistance (136). In a recent  study with young 
Finnish adults it was found that the ratio between hs-CRP and leptin was independent of obesity 
and cardiovascular risk factors. Because the effect of leptin was not restricted to obesity, it was 
suggested that leptin might regulate development of chronic low-grade inflammation at all levels 
of body weight (137). In a prospective population-based study leptin levels significantly 
predicted the development of the MetS, independently of baseline BMI (138).  
  Resistin is a dimeric protein that is highly expressed in mouse adipose tissue (139). In 
humans resistin is mainly produced by macrophages and is involved in an inflammatory process 
that may be related to atherosclerosis (140). Abdominal fat depots showed a 418% increase in 
resistin mRNA expression compared with thigh fat (141). 
   Visfatin, originally identified as a pre-B-cell colony-enhancing factor, is highly expressed in 
visceral adipose tissue, and plasma visfatin levels correlated with obesity (142). Visfatin lowers 
blood glucose levels in mice, and in vitro visfatin directly activates the insulin-receptor signalling 
cascade (142). However, in humans no correlation was found between plasma visfatin levels 
and parameters of insulin sensitivity (143). 
   High levels of plasminogen activator inhibitor (PAI)-1 contribute to the procoagulant state in 
the MetS. Although PAI-1 is synthesized in many cell types, adipose tissue is the major source 
of PAI-1, and circulating PAI-1 levels correlate with visceral obesity (144). In obese individuals 
PAI-1 levels are increased in those with MetS (145). The fibrinolytic system could play a role in 
the regulation of adiopose tissue development and insulin signaling in adipocytes (146).  
  Apelin is a bioactive peptide that was originally identified as the endogenous ligand of orphan 
G-protein-coupled receptor APJ (147). It has been suggested that production of apelin in the 
obese might be an adaptive response to obesity-related disorders such as mild chronic 
inflammation (148). 
   The most recently discovered adipokines are hepcidin and vaspin. Hepcidin was discovered 
in 2001 as a urinary antimicrobial peptide synthesized in the liver, and was later identified as an 
adipokine. It has a function as a key regulator of iron homeostasis, hypoxia and inflammatory 
stimuli (149,150). Vaspin was discovered in 2005 as a serpin (serine protease inhibitor)  
produced in visceral adipose tissue. It might also constitute  a compensatory mechanism in 
response to obesity and inflammation (151).Vaspin concentrations are higher in female 
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compared to male subjects. In the normal glucose-tolerant (NGT) group, circulating vaspin 
significantly correlated with BMI and insulin sensitivity (152). 
 
Table 2. Overview of key adipokines (modified from 120, 154). 
 
Adipokine                      Key Properties                                                 Secretion in obesity     
                                                                                                                                     
Tumour Necrosis-          Pro-atherogenic, diabetogenic,                                              Increased 
Factor (TNF)- Į              paracrine role in adipocyte                                                        
                                               Decreased insulin signalling 
                                               Increased secretion of other inflammatory 
                                               mediators                                                
Interleukin (IL)-6           Promotes inflammation, pro-atherogenic,                                Increased 
                                     diabetogenic                                                             
                                                Increased  vascular inflammation 
                                                Increased hepatic C-reactive protein production 
                                                Decreased insulin signalling   
                                                Possible enhances glucose disposal and lipolysis 
C-reactive protein          Promotes inflammation, pro-atherogenic,                               Increased 
                                      diabetogenic          
                                                Marker of chronic low-grade inflammation 
                                                Predicts adverse cardiovascular outcomes 
Adiponectin                   Anti-atherogenic, anti-diabetogenic                                        Decreased  
                                                Decreased differentation of   
                                                macrophages into foam cells 
                                                Decreased atherogenic vascular remodelling 
                                                Decreased hepatic glucose output  
                                                Increased insulin sensitivity 
Leptin                             Inhibits appetite and weight gain in hypothalamus                 Increased 
                                                 Decreased insulin signalling 
                                                 Pleiotropic actions             
Resistin                          Exarberates insulin resistance                                                Increased 
                                                Decreased insulin signalling 
                                                Decreased endothelial function 
                                                Increased vascular smooth muscle proliferation  
Visfatin                           Activates insulin signalling in mice                                          Increased 
Plasminogen Activator-  Pro-atherogenic, pro-coagulant                                              Increased  
Inhibitor (PAI)-1                    Increased atherothrombotic risk                              
Apelin                             Adaptive response to obesity (?)                                            Increased  
                                                 Increased by TNF 
Hepcidin                          Regulator of iron homeostasis and inflammatory                  Increased 
                                        stimulus 
Vaspin                             Compensatory mechanism                                                    Increased 
                                             to obesity and inflammation (?)                                             
Interleukin-1 Receptor     Adaptive response to inflammation                                       Increased   
antagonist (IL-1 Ra)              Prevents IL-1 responses 
                                              Acute phase reactant 
                                              Increases insulin resistance                                 
 
   Adipose tissue produces, presumably as an adaptive response, anti-inflammatory factors 
such as interleukin-1 receptor antagonist (IL-1 Ra), which binds competitively to the type 1 
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receptor without triggering activity within the cell (153). The role of IL-1 Ra is discussed later in 
section 2.2.5.3. 
   Accumulating evidence suggests that an increase in visceral abdominal fat mass is the 
primary perturbation in the pathogenesis of the MetS, providing mediators, adipokines, for 
cross-talk with other tissues and finally leading to insulin resistance and vascular disorders 
(154).  
 
 
2.2.2. Insulin resistance and glucose intolerance 
 
Insulin is a hormone with important metabolic functions. By stimulating the uptake of glucose 
into skeletal muscle cells and adipocytes and inhibiting hepatic glucose production, insulin can 
be regarded as the most important regulator of the plasma glucose level. In addition, insulin 
stimulates lipogenesis and glycogen and protein synthesis in adipose tissue, liver and skeletal 
muscle cells and inhibits glycogenolysis, lipolysis and protein breakdown (155).  
   Insulin resistance can be defined as an insufficient response of the target organs (liver, 
skeletal muscle cells and adipose tissue) to physiological plasma insulin levels. A disruption in 
the insulin signalling transduction pathway is considered to be the most important underlying 
mechanism. Insulin resistance has different effects in different organs and leads to a 
compensatory increase in the production of insulin by pancreatic beta-cells, resulting in 
hyperinsulinemia (155). The impact of genetic factors has been demonstated by reduced insulin 
sensitivity in certain ethnic groups (156) and in first-degree relatives of T2DM patients (157). 
Also free fatty acids and TNF-Į and other adipokines play a central role. Insulin resistance is a 
strong predictor of the risk for developing T2DM (158). In large prospective population studies 
hyperinsulinemia (a surrogate marker of insulin resistance) has also predicted CVD and 
mortality (159-161).  
   The hyperinsulinemic euglycemic clamp is widely recognized as the gold standard for 
measuring insulin sensitivity (24). However, it is complex, costly and time consuming, and 
therefore not suitable for population-based studies. The homeostasis model assessment 
(HOMA-IR) of insulin resistance is a simple and less expensive method and therefore widely 
used in epidemiological studies. HOMA-IR gives an estimate of basal insulin resistance from the 
mathematical modeling of fasting plasma glucose and insulin concentrations. The correlation 
with clamp-measured insulin sensitivity is generally around -0.80 (162). Fasting insulin level has 
also been used as a marker of insulin resistance in epidemiological studies. The correlation of 
insulin levels and clamp measured insulin sensitivity is around -0.70 in subjects with normal 
glucose tolerance (26). In the large DECODE  study, hyperinsulinemia, defined by the highest 
quartile  for fasting insulin, was significantly associated with cardiovascular mortality in both 
men and women independently of other risk factors (163). Hyperinsulinemia and insulin 
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resistance may partly represent different phenotypes (164). The quantitative insulin sensitivity 
check index (QUICKI) is  an alternative method of measuring insulin sensitivity in large 
population studies, and is determined by fasting glucose and insulin levels. QUICKI correlates 
significantly with the glucose clamp method (165,166), and predicts better than fasting insulin 
the onset of type 2 diabetes (167).  
   The biological action of insulin is mediated via the insulin receptor, which is widely expressed 
in human tissues. Insulin resistance is believed to result from a defect inherent in the insulin 
signalling pathway, which is common to many insulin-responsive cell types. Individuals who lack 
the insulin receptor or have antibodies against it develop severe insulin resistance (168). 
However, this intrinsic receptor defect does not explain the link between obesity and insulin 
resistance. As insulin is anabolic and enhances fat storage, insulin resistance in adipose tissue 
might be expected to mitigate obesity (169). 
   An alternative theory postulates that insulin resistance arises when pathological levels of 
humoral factors disrupt insulin signalling in responsive tissues. This humoral theory emerged 
from the recently recognized role of adipose tissue as a secretory organ (170), and provided an 
obvious link between obesity and insulin resistance. In 2005 this was confirmed and extended 
by demonstrating that inflammation in the liver can  be the primary source of systemic factors 
that lead to the development of insulin resistance (171). Insulin has been found to be an anti-
inflammatory hormone. It has been shown to suppress several proinflammatory transcription 
factors, such as nuclear factor-țB, EGR-1 and activating protein-1 and the corresponding genes 
regulated by them, which mediate inflammation (172,173). Impairment in the action of insulin 
because of insulin resistance would thus result in the activation of these proinflammatory 
transcription factors and an increase in the expression of the corresponding genes (174). 
    The integration of all these mechanisms might lead to so called  endoplasmic reticulum (ER) 
stress. This theory was presented by Hotamisligil (175). It is believed that inflammatory 
responses in obesity can be triggered in the adipocyte or macrophages by extracellular 
mediators such as cytokines or lipids, or initiated through ER stress. Signals from all these 
mediators converge on inflammatory signalling pathways. The mediators include kinases: c-Jun 
NH2-terminal kinase and protein kinase C (PKC), and reactive oxygen species (ROS). Once 
activated they lead to the production of additional inflammatory mediators through 
transcriptional regulation and this starts a vicious circle. They also directly inhibit insulin receptor 
signalling (175). 
   Glucose intolerance develops when insulin secretion from pancreatic ȕ cells fails to 
compensate for insulin resistance in target tissues. Insufficient insulin action in the liver leads to 
increased gluconeogenesis and to glycogenolysis of stored glycogen. An increase in FFA 
levels, due to adipose tissue insulin resistance, contributes to glucose production by stimulating 
gluconeogenesis (176). Rising hyperglycemia per se also contributes via so-called glucose 
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toxicity to impaired insulin secretion (177). Diminished insulin secretion patterns, which might be 
genetically determined, are also observed in first-degree relatives of T2DM even during 
euglycemia (178,179). 
   In many subjects, atherosclerosis precedes the development of type 2 diabetes, and 
cardiovascular complications are often present in newly diagnosed type 2 diabetes patients. In 
the Euro Heart Survey  31% of patients with acute or chronic CHD had diabetes. In the patients 
with acute CHD, 36% had IGT, and 22% had newly detected diabetes. In the stable group these 
proportions were 37% and 14%. Only about 30% of the CHD patients had normal glucose 
tolerance (180). On the other hand diabetes without prior myocardial infarction was CHD 
equivalent in an 18-year follow-up study of Finnish subjects, if prior CHD was defined as 
myocardial infarction. When less stringent criteria for prior CHD were used (myocardial 
infarction or ischemic ECG changes or angina pectoris), type 2 diabetes carried a larger risk 
than prior CHD, especially in women (181). The metabolic syndrome and diabetes  carry 
increased risk of stroke (182). These findings indicate that diabetes and cardiovascular disease 
may share an underlying cause (13,183). It is possible that this common link between T2DM 
and CVD is insulin resistance (184).  
 
2.2.3. Dyslipidemia 
 
Dyslipidemia in the MetS is characterized by elevated triglycerides (TG) and low levels of HDL-
C (20,25,29,30). Plasma LDL cholesterol (LDL-C) levels are often normal in the MetS. A 
common finding, however, is that LDL particles are smaller and denser than normal (185), a 
state believed to be associated with increased cardiovascular risk. 
   The predominant mechanism in the insulin resistance setting is increased influx of FFAs into 
the liver, which increases hepatic production of triglyceride-rich VLDL particles (186). Insulin 
resistance may also lead to impaired LPL activity, and thus reduced triglyceride clearence may 
contribute to elevated triglyceride levels in the MetS (187). A recent study links postprandial 
elevation of triglyceride-rich lipoproteins (TRL) to high hepatic fat content and low adiponectin 
levels. Elevation of postprandial TRL exposes the liver to excess FFA and can influence 
hepatocellular lipid metabolism, leading to hepatic steatosis and disturbance in the insulin 
signaling pathways (188). Hypertriglyceridemia is an excellent reflection of the insulin resistant 
condition and one important criteria for diagnosis of the MetS. 
   In the presence of hypertriglyceridemia, a decrease in the cholesterol content of HDL results 
from decreases in the cholesterol ester content of the lipoprotein core along with variable 
increases in triglycerides making the particle small and dense. This process is in part a function 
of the cholesteryl ester transfer protein (189). This change in lipoprotein composition also 
results in increased clearance of HDL from the circulation (190). The relation of these changes 
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in HDL to insulin resistance are probably indirect, arising in concert with the changes in 
triglyceride-rich lipoprotein metabolism (53). 
   In addition to HDL, the composition of LDL is modified. With fasting serum triglycerides > 2,0 
mmol/l, almost all individuals have a predominance of small dense LDL (191), which might be 
more atherogenic than buoyant LDL. The propensity towards small dense LDL is attributable to 
its facilitated transit through the endothelium and tight adherence to intimal proteoglycans, in 
addition to its susceptibilty to oxidation (192). All these changes are not independent, but 
related to concominant changes in other lipoproteins and risk factors (193). 
 
2.2.4. Blood pressure 
 
 The association of elevated blood pressure  and insulin resistance or hyperinsulinemia was first 
reported more than 40 years ago (194). Insulin resistance is found to be directly correlated with 
the severity of hypertension (195). About a half of hypertensive subjects are insulin-resistant 
(196,197). The association of hyperinsulinemia and hypertension has also been confirmed in 
prospective studies. In the San Antonio Heart Study (198), and in Swedish middle-aged men 
(199) and women (200), fasting insulin levels were associated with hypertension 8-12 years 
later. 
   The underlying mechanisms connecting insulin resistance and hypertension are not  clear. 
Insulin is a vasodilator when given intravenously to normal-weight subjects (201), with 
secondary effects on  natrium re-absorption in the kidney (202). In insulin-resistant subjects the 
vasodilatory effect of insulin is lost, possibly impairing endothelium-derived nitric oxide (NO) 
production (201), but the renal effect of natrium reabsorption is preserved (202). 
Hyperinsulinemia also increases the activity of the sympathetic nervous system (203) and 
modifies transmembrane cation transport (204). Furthermore, locally enhanced glucocorticoid 
activity in the adipose and muscle tissue of obese subjects contributes to metabolic 
abnormalities associated with the MetS, and this may lead to hypertension via the activation of 
the renin-angiotensin system (205). The role of adipokines and cytokines in hypertension and 
the MetS have not yet been established (206), but adiponectin concentrations have been found 
to be low in subjects with essential hypertension (207).  
   Insulin resistance and hyperinsulinemia may in the long term promote increases in blood 
pressure, complementing many other mechanisms in the pathogenesis of hypertension, or they 
might even be the primary defect (208).   
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2.2.5. Low-grade inflammation and adiponectin in the metabolic syndrome   
 
The finding that TNF-D is overexpressed in the adipose tissue of obese mice provided the first 
clear link between obesity, diabetes and chronic low-grade inflammation (58). However, the first 
indication of this pathophysiological connection between diabetes and inflammation was 
presented over 130 years ago, when Ebstein reported that high doses of salicylate improved 
glucosuria in diabetic patients (209).  
   This idea was then forgotten until a group of epidemiologists in the mid-1990s discussed the 
possibility that diabetes and atherosclerosis have common antecedents (the”common soil 
hypothesis”) (13). In 1998 Pickup and Crook (210) finally laid out a more specific 
pathophysiological hypothesis. Based on the observation that dyslipidemia, common to people 
with T2DM, is also a feature of the experimental disease and naturally occurring acute-phase 
reactions, Pickup and Crook proposed that in individuals with an innately hypersensitive acute-
phase response, long-term lifestyle and environmental stressors, such as high-fat diet, produce 
disease (T2DM) instead of repair. They further explained that the innate immune system is 
primarily responsible for the acute-phase response, a self-limiting process induced by a variety 
of stressors (infection, tissue injury, and malignancy) causing a number of cells (macrophages, 
adipocytes, and endothelial cells) to secrete cytokines (interleukin (IL)-1, IL-6 and TNF-D), 
which act on the liver to synthesize acute-phase proteins (fibrinogen, C-reactive protein, serum 
amyloid A, and others). Due to its self-limiting nature, the acute-phase response is aimed at 
restoring the homeostasis disturbed by an acute stressor. However, in response to chronic 
stressors, the system may become allostatic, i.e., the sustained effort to acutely battle 
challenges may ultimately result in overload of the system’s resources, and thus the system 
breaks down (211) and type 2 diabetes develops (212). Adipose tissue produces, presumably 
as an adaptive response to chronic stress, anti-inflammatory factors such as interleukin-1 
receptor antagonists (IL-1 Ra) (153).  
2.2.5.1. Adiponectin 
 
Adiponectin is an anti-inflammatory cytokine produced exclusively by adipocytes. Physiological 
plasma adiponectin concentrations are very high (5-10 Pg/ml, higher in women than in men, 
accounting for about 0.05% of total serum proteins) and visceral obesity has been shown to be 
negatively correlated with plasma adiponectin levels (213). The mechanism by which (visceral) 
obesity leads to a reduction in plasma adiponectin levels has not yet been elucidated (155), but 
reduced adiponectin levels can be caused by interactions of genetic factors such as single 
nucleotide polymorphism 276 in the adiponectin gene itself and enviromental factors, i.e., 
lifestyle changes that cause obesity, such as a high-fat diet and sedentary lifestyle (214). 
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   Adiponectin, also termed Acrp30 (adipocyte complement-related protein of 30 kDa) (9), 
AdipoQ (215), apM1 (adipose most abundant gene transcript 1) (216) or gelatin binding protein 
of 28 kDa (217), was originally identified independently by 4 groups using different approaches 
in 1995-96. Adiponectin exists in a wide range of multimer complexes in plasma and combines 
via its collagen domain to create 3 major oligomeric forms: a low-molecular weight (LMW) 
trimer, a middle-molecular weight (MMW) hexamer, and high-molecular weight (HMW) 12- to 
18-mer adiponectin (218). 
   Several mechanisms for the metabolic effects of adiponectin have been described (169). In 
the liver, adiponectin enhances insulin sensitivity, decreases the influx of NEFAs, increases 
fatty acid oxidation, and reduces hepatic glucose output. In muscle, adiponectin stimulates 
glucose use and fatty acid oxidation. Within the vascular wall, adiponectin inhibits monocyte 
adhesion by decreasing the expression of adhesion molecules, inhibits macrophage 
transformation to foam cells by inhibiting scavenger receptors, and decreases proliferation of 
migrating smooth cells in response to growth factors. Adiponectin has a sticky nature, binding to 
collagen I, III and V, which are present in vascular intima. Hence the name adiponectin. In 
addition, adiponectin increases nitric oxide production in endothelial cells and stimulates 
angiogenesis.These effects are mediated via increased phosphorylation of the insulin receptor, 
activation of AMP-activated protein kinase, and modulation of the nuclear factor NB pathway. 
   White adipose tissue is the only source of adiponectin, and in contrast to other adipokines, 
adiponectin level is inversely associated with insulin resistance, obesity, the MetS (219,220), 
T2DM (221), and atherosclerosis (222,223). In prospective studies a low level of adiponectin 
has been predictive of the development of insulin resistance, T2DM , hypertension and 
cardiovascular disease (224-228). High adiponectin levels have been found to be protective 
against development of T2DM (229,230). Pima Indians with high concentrations of adiponectin 
were 40% less likely to develop T2DM than those with low concentrations after adjustment for 
BMI, indicating that adiponectin could be used as a predictor of the future development of T2DM 
(229).  
   In both humans and rodents females have higher plasma adiponectin levels than males, 
suggesting that hormones regulate the production of adiponectin, although it is controversial 
how these hormones, such as estrogen and testosterone, are involved (125,214). Relatively 
little is known about how plasma adiponectin is metabolized and cleared from the circulation, 
but it is detected in urine in T2DM subjects and healthy males, and shows elevated levels in 
patients with macro-albuminuria (231). 
   According to the adiponectin hypothesis, a therapeutic strategy for the treatment of insulin 
resistance, type 2 diabetes, the MetS, and cardiovascular disease may include the elevation of 
plasma adiponectin levels by the upregularion of adiponectin receptors, Adipo R1 and Adipo R2 
(232), or the development of adiponectin receptor agonists (214). The increase in the level of 
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adiponectin is observed after administration of insulin-sensitizing thiazolidinediones (TZD) 
(243), which serve as agonist for the transcription factor PPAR,  and angiotensin II receptor 
blockers (234) or angiotensin-converting enzyme inhibitors (235). Also weight loss (236), Roux-
en-Y gastric bypass surgery (237) and some dietary factors such as soy protein (238) and fish 
oils (239) increase adiponectin levels. Physical training resulted in increased adiponectin 
receptors 1 and 2 mRNA expression in subcutaneous fat, and thus may mediate the 
improvement of insulin resistance in response to exercise (240). 
   The exact role of adiponectin in health, the MetS, insulin resistance, T2DM and 
cardiovascular disease is not  clear, but it is assumed to play a key role in these contexts and 
can be called an endogenous insulin sensitizer. It has been suggested that a low level of 
circulating adiponectin represents an independent risk factor and a possible biomarker for the 
metabolic syndrome (241). The idea of increasing the level of adiponectin by upregulation of 
receptors makes adiponectin an even more promising treatment option in the future (11). 
2.2.5.2. C-reactive protein  
 
C-reactive protein was first described in 1944. An increase in the concentration of serum 
capsular swelling protein (later named as CRP) was seen in a patient with acute myocardial 
infarction accompanied by a rise in body temperature and white blood cell count (242). It was 
four decades later that this increase in CRP in unstable coronary disease was recognized as 
potentially reflecting more than an inflammatory response to necrosis (243). Since then many 
epidemiological studies have demonstrated a significant association between elevated CRP and 
the prevalence of underlying CVD, the risk of recurrent CVD events among those with 
established disease, or the incidence of first CVD event among those at risk (244). In particular 
it has been shown that there is a consistent and robust relationship between high-sensitivity 
CRP (hs-CRP) and the risk of future CV events (245,246). High CRP levels are associated with 
an increased risk of CVD among subjects with the MetS or diabetes, even independently of 
currently established lifestyle risk factors, blood lipids, and glycemic control (247,248), although 
in the Framingham offspring study discrimination of subjects at risk of CVD events using both 
MetS and CRP was not better than using either alone (249). 
   After the findings of the association between CRP and CHD, a relationship with obesity and 
elevated CRP and IL-6 was observed in healthy subjects in 1999 (12). Obesity was an 
important determinant of CRP concentration in monozygotic twins, independent of genetic 
influences (250). Higher BMI (251,252) and central obesity was seen as a major determinant of 
increased CRP in the MetS (253) and in T2DM (254).  
   The association between CRP and a number of the components of the MetS have been 
described, supposing that the MetS is associated with a systemic inflammatory response (255). 
An increment of 1 mg/L in CRP over 12 years in elderly Finnish women was associated with a 
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37% increase in the risk of developing the MetS during the same period after adjustment for 
baseline age, smoking, the use of drugs for lipids, hormone replacement therapy, and prevalent 
CVD (256). The optimal CRP cut-off point for the MetS was 0,65 mg/L in a Japanese healthy 
population (257).An association between CRP and insulin resistance (258,259), fasting and 
post-load glucose  (260,261) and risk for developing diabetes (262-264) has been found in 
many studies. 
   Because of all these data linking CRP and cardiovascular disease it has been suggested that 
CRP could be added to the definition of the MetS. The cut-off point is suggested to be 3 mg/L 
(265). However, in a Mendelian randomisation study no evidence was found of a causal link 
between CRP and pathology of the components of the MetS (266). Nevertheless reciprocal 
association between hs-CRP and adiponectin has been observed in many studies (267,268), 
suggesting that decreased adiponectin levels might be fundamentally associated with the early 
stage of low-grade inflammation. In contrast, the KORA S4 study  did not show the association 
between hypoadiponectinemia and proinflammation (269).  
2.2.5.3. Interleukin-1 Receptor antagonist  
 
Inflammation in autoimmune diseases is characterized by an imbalance between pro- and anti-
inflammatory cytokines.The members IL-1D and IL-1ȕ of the IL-1 cytokine superfamily are 
strong inducers of inflammation (270,271). IL-1 Receptor antagonist (IL-1 Ra) acts in an 
antagonist manner and serves as a natural compensatory mechanism for the IL-1-induced 
disease process (272). When IL-1 occupies its receptor, various proinflammatory events are 
initiated, but when IL-1 Ra occupies the receptor, no such events are initiated, because IL-1 
cannot bind to cells (153). 
   In healthy individuals, IL-1 Ra is detectable in plasma, in contrast to usually undetectable 
levels of IL-1ȕ (271). White adipose tissue is an important source of IL-1 Ra (273). IL-1 Ra 
levels are increased in human obesity (274) and may contribute to the development of insulin 
resistance (275). In nondiabetic offspring of diabetic probands with the MetS IL-1 Ra and IL-1 ȕ 
were found to be highly elevated, whereas in the same study population TNF-D did not differ 
between the factor score tertiles (276). IL-1 Ra has also been found to be the most sensitive 
marker of cytokine response in the prediabetic state (277); however when diabetes develops, 
the levels of IL-1 Ra fall (278).  
   IL-1 Ra was also found to be a sensitive marker of clinical instability in CAD patients (279), 
levels of IL-1 Ra correlated with extent of myocardial loss in patients with acute myocardial 
infarction (280), and IL-1 Ra genotype was associated with coronary atherosclerosis in T2DM 
patients (281). 
38
   A recent preliminary study with anakinra (a recombinant human IL-1 Ra), lasting for 13 weeks, 
showed that anakinra did not affect insulin resistance in type 2 diabetic patients. Also BMI 
remained stable, but  glycemic control improved slightly, most likely through enhanced beta-cell 
secretory function (282). This may indicate that the effects of IL-1 Ra are different in 
prediabetes compared to established type 2 diabetes, but further studies are needed to confirm 
these findings. 
 
2.2.6. Other features in the metabolic syndrome 
 
Insulin resistance is accompanied by many other alterations that are not included in the 
diagnostic criteria for the metabolic syndrome. Increases in uric acid, pro-thrombotic factors 
(fibrinogen,  plasminogen activator inhibitor (PAI)-1), serum viscosity, asymmetric 
dimethylarginine (an endogenous inhibitor of NO synthase, which plays an important role in 
endothelial dysfunction), homocysteine, leucocyte count, pro-inflammatory cytokines, the 
presence of microalbuminuria, non-alcoholic fatty liver disease, polycystic ovarian disease, 
obstructive sleep apnea, cholesterol gallstones and a decrease in adiponectin are all associated 
with insulin resistance (283). Cigarette smoking (284) and a sedentary lifestyle (285) can also 
produce many of the major criteria of the syndrome and beyond. Genetics also plays an 
important role between enviromental factors and the components of the MetS. 
2.2.6.1. Prothrombotic state   
 
The prothrombotic state present in the MetS is due to numerous changes in the coagulation 
pathway, fibrinolytic pathway and platelet function (286). Increased plasma levels of fibrinogen 
reflect the activation of the coagulation pathway, and increased levels of fibrinogen are 
associated with low-grade inflammation and insulin resistance in the MetS (287), and with 
impaired fibrinolysis (288). Fibrinolytic dysfunction, as a consequence of increased levels of 
PAI-1, also has independent value for future cardiovascular disease (289,290). Insulin 
resistance has been associated with increased levels of coagulation factors VII-IX (291) and 
increased red cell blood count (292). Platelet function is also disturbed in insulin resistance. 
Platelets from obese insulin-resistant subjects have reduced sensitivity to the known anti-
aggregatory effect of insulin (293). All these might contribute to the increased risk for the 
development of cardiovascular disease in people with the MetS. 
2.2.6.2. Hyperuricemia 
 
Serum uric acid is the major product of the purine metabolism. In cross-sectional studies, uric 
acid correlates with the components of metabolic syndrome: hypertension, obesity, low HDL 
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cholesterol, hypertriglyceridemia, and insulin resistance (294-296). In the Finnish Diabetes 
Prevention Study (DPS) baseline uric acid and changes in it during the follow-up were related to 
corresponding changes in fasting and post-load glucose and insulin levels (297). In the 
Rotterdam population-based study serum uric acid was a strong and independent risk factor for 
diabetes during a follow-up of 10.1 years (298). Although hyperuricemia and hyperinsulinemia 
are closely linked, the mechanism behind this is obscure. The most promising hypothesis is that 
this occurs at renal level: renal tubular function is influenced by hyperinsulinemia, urinary uric 
acid clearence decreasing with decreasing insulin-mediated glucose disposal (295). The 
importance of hyperuricemia as a possible treatment target is not known. 
2.2.6.3. Endothelial dysfunction 
 
The endothelium is involved in the regulation of vascular tone, platelet adhesion, coagulation, 
fibrinolysis and leukocyte adherence, but the term endothelial dysfunction specifically refers to 
impaired endothelium-dependent relaxation caused by a loss of NO bioacticity in the vessel wall 
(299). Endothelial cells synthesize a wide variety of other vasoactive mediators, and the 
balance between them may be an important contributing factor to the vascular function of blood 
vessels. Endothelin-1 is the most powerful vasoconstrictive factor yet discovered (300), and has 
been found to be elevated in postmenopausal type 2 diabetic women (301). Endothelial 
dysfunction has been shown to predict future adverse CVD events (302) and type 2 diabetes 
(303). Endothelial dysfunction characterizes all insulin-resistant conditions and is thought to link 
insulin resistance to CVD (299). Reduction of inflammatory cytokine concentrations and 
improvement of endothelial functions have been found at the same time in obese women after 
weight loss (304). In a study with offspring of type 2 diabetic patients, the levels of adhesion 
molecules, relating to endothelial dysfunction, were not elevated. Instead, a correlation was 
found between inflammatory markers and adhesion molecules, suggesting that low-grade 
inflammation may precede elevated levels of adhesion molecules (305). 
   Endothelial dysfunction is linked to insulin resistance and other associated features of the 
MetS. It has been suggested that dysfunction of the endothelium in large and medium-sized 
arteries plays a central role in atherogenesis, whereas dysfunction at the peripherial vascular 
endothelial level plays the primary role in the pathogenesis of insulin resistance (306). 
2.2.6.4. Microalbuminuria 
 
Microalbuminuria is a component of the MetS as defined by the WHO (20). Microalbuminuria is 
a well established marker for incipient nephropathy in patients with diabetes (307). It is also 
associated with increased CVD in both diabetic and non-diabetic subjects (308,309). Previous 
studies reported that microalbuminuria in non-diabetic subjects was associated with MetS, and 
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could be a component of it (310,311). However, multiple logistic regression analysis in diabetic 
and non-diabetic subjects separately showed that microalbuminuria was independently 
associated only with hypertension, diabetes and waist-hip-ratio, but not with the other variables 
of the MetS. It is therefore likely that microalbuminuria is more a complication of hypertension 
and diabetes, showing vascular disturbances, and not an integral part of the MetS (22,23). 
2.2.6.5. Polycystic ovary syndrome  
 
Polycystic ovary syndrome (PCOS) is a heterogeneous clinical entity characterized by signs 
and symptoms of hyperandrogenism and anovulatory disorders often associated with infertility 
and obesity. The underlying pathogenesis remains uncertain, although key components in the 
syndrome may be insulin resistance and hyperinsulinemia (312, 313). However, in a Finnish 
population-based study surprisingly few women with the MetS had symptoms suggestive of 
PCOS, in comparision with obese and lean women. These results suggest that at the population 
level PCOS only accounts for a distinct subgroup of the MetS (314). 
2.2.6.6. Depression 
 
In 1674, Thomas Willis speculated that diabetes was caused by "long sorrow and other depressions"(315). 
Since then many studies have found similarities in the pathophysiology of depressive disorders and 
alterations in the metabolic network. It has been proposed that depressive symptoms be classified as" 
metabolic syndrome type II" (316). In women with suspected CHD, the MetS was independently 
associated with depression but explained only a small portion of the association between depression and 
incident CVD (317). In a recent population-based 7-year follow-up study nondepressed women and men 
with the MetS at baseline were twice as likely to have depressive symptoms at follow-up compared with 
the non-depressed members of this cohort without the MetS at baseline (318). In the Diabetes Prevention 
Program (DPP) the risk of developing diabetes was associated more often with the use of antidepressants 
than other metabolic factors (319).The high rate of depressive symptoms in the MetS suggests that the 
MetS may be an important predisposing factor to the development of depression. Effective prevention 
and treatment of the MetS could also be important for the prevention of depression. 
 
 2.3. Genetics of the metabolic syndrome 
 
Genetic factors influence the components of the MetS and predispose subjects to the MetS 
together with changing enviromental and behavioral factors. The genetic factors contributing to 
the syndrome are still largely unknown. However, it is likely that a large number of genes 
interact with each other and the environment, and thus contribute to the risk for the MetS (320). 
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   According to the "thrifty gene" hypothesis, the genes that were benificial to the survival for our 
ancestors during famines by maximizing the ability to store energy as fat, predispose nowadays 
to obesity, MetS and T2DM when exposed to a sedentary lifestyle and high caloric intake (321). 
One recently found candidate for this thrifty gene is adipose (Adp), which appears to be 
involved in an ancient pathway that regulates fat accumulation (322).  
    Racial differences in the risk (323), familial clustering of the MetS (324,325) and twin studies 
(326) have given grounds for the argument that genetic factors contribute to the MetS. Insulin 
resistance also clusters in families. In the Botnia study 45% of the first degree relatives of 
patients with T2DM were insulin resistant compared with 20% of individuals without a family 
history of diabetes (157). The estimates of the heritability of obesity vary greatly, but generally 
about 40-70% of the variation in body weight can be explained by genetic factors (327,328). 
Genes are believed to explain about 60% of the variance in abdominal fat in menopausal 
women (329). In the Botnia-study, first-degree relatives of T2DM had a higher waist-hip-ratio 
than their spouses without a family history of T2DM (157). Other components of the MetS also 
exhibit strong genetic components: heritability levels ranging from 25 to 45% for TGs, 50-60% 
for total cholesterol, 30-55% for HDL-cholesterol, 30% for systolic blood pressure, 20-30% for 
diastolic blood pressure, 50%  for hypertension (330)  and about 30% for microalbuminuria 
(331). 
   Two approaches have been used in the search for the thrifty genes: the candidate gene 
approach and genome-wide scanning (332). The candidate gene approach aims to identify 
genes on the basis of information about their function. Genes affecting body weight and fat 
distribution, lipolysis, fuel oxidation or skeletal muscle glucose metabolism could predispose to 
the MetS (333). Such candidate genes include ȕ2- and ȕ3-adrenergic receptors, hormone 
sensitive lipase, uncoupling proteins, peroxisomase proliferators-activated receptor gamma-2, 
TNF-Į, insulin receptor substrates and glycogen synthase, as well as many others (334). 
   Growing interest is being shown in the genes controlling adiponectin and CRP. The ADIPO 
gene encoding adiponectin has been mapped to chromosome 2q27 (335). There are data that 
genetic variation within the ADIPO gene may be part of the genetic determinants of risk for 
type 2 diabetes and insulin resistance via the modulation of adiponectin levels (336,337). CRP 
concentration in old people may in part be determined genetically by the CRP gene (338). CRP 
may also suppress adiponectin gene expression partially through the PI-3 kinase pathway, and 
thus might represent a possible mechanism by which CRP regulates insulin sensitivity (339). 
   The growing epidemic of obesity and MetS may be explained by gene-environment 
interactions (340). Alterations in physical activity can have different effects on abdominal fat 
(341) and even diastolic blood pressure, as seen in the HERITAGE Family Study (342). In the 
Finnish DPS it was also found that genetic variation may modify the magnitude of the beneficial 
effects of physical activity on characteristics of the MetS in persons with IGT (343). 
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   An increasing understanding of the role of genes in the development of the MetS may reveal 
genetic variants that, in combination with conventional risk factors, may help to predict the risk 
for an individual to developing the MetS and to find different preventive methods and therapy for 
genetically different subjects. 
 
2.4. Life style and other factors in the metabolic syndrome 
 
During the last century in the western world, industrialization has provided increasing access to 
large quantities of mass-produced, high caloric foods and many labour saving and 
transportation devices, abolishing starvation and heavy manual work. As stated earlier, our 
genes are ancestral energy-conserving, and the result of this combination of genes and 
industrialization is an epidemic of obesity, MetS, type 2 diabetes and CVD. 
   Caloric-restricted diet extends the life-span of laboratory rodents up to 50%. This finding has 
been represented in organisms ranging from yeast to primates, and is  the most robust method 
currently known of extending the lifespan of higher organisms. Caloric restriction  even slows or 
prevents major ageing related diseases in rodent models (344). One mechanism behind this 
might be sirtuins, which have some unknown role in regulating ȕ-cell function in mammals 
(345). Theoretically, the same finding has recently been reported in Cuba, where the economic 
crises of 1989-2005 resulted in reduced energy intake, increased physical activity, and 
sustained population-wide weight loss. The prevalence of obesity declined from 14% to 7%. 
During 1997-2002, there were declines in death attributed to diabetes of 51%, to CHD of 35%, 
to stroke of 20%, and to all causes of 18%. However, a modest increase in the all-cause death 
rate among elderly subjects, was observed (346). 
   Sedentary lifestyle is clearly associated with several features, especially abdominal obesity, of 
the MetS (285,347), but no good prospective studies have shown that a lifestyle intervention 
can prevent the evolution of the MetS and its complications T2DM and CVD. The most well-
known preventive studies (both dietary and increased physical activity) have involved subjects 
with IGT  and the end-point has been the prevention of diabetes. Both the DPS (348) and DPP 
(349) studies showed the same 58% reduced risk of diabetes in the lifestyle intervention group 
compared with the control group. The intervention goals in DPS were to reduce body weight (a 
reduction of 5% or more of baseline weight), limit dietary fat (<30%) and saturated fat (<10%) of 
total energy consumed, and to increase dietary fibre intake (15 g/100 kcal or more) and physical 
activity ( 30 minutes/day) (348). In the secondary analysis of the DPS study, the effects of the 
lifestyle intervention on MetS and its components were a significant reduction in the prevalence 
of the Mets (OR of 0.62) and especially the component of abdominal obesity (OR 0.48). Other 
components of the MetS did not show significant effects between the groups (350). In many 
studies it is difficult to distinguish between physical activity and dietary changes, but all the 
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studies and systematic reviews published thus far show a constant positive effect of physical 
activity on the prevention of T2DM and MetS (351-355). 
   Exercise has anti-inflammatory effects by suppressing TNF-Į and IL-6 production (356). 
Inflammatory markers, such as baseline CRP, were found in the DPS to be the best 
immunological marker of lifestyle changes for progression to overt diabetes (357). In the 
HERITAGE Family Study CRP levels reduced in response to exercise with high initial CRP 
levels (358). Exercise-induced increase in adiponectin levels was not found despite decreased 
abdominal adiposity and improved insulin sensitivity in T2DM men (359). 
   Dietary aspects are also involved in the inflammatory processes. It is believed that a 
macronutrient (energy-dense, high fast carbohydrate) diet results in the inability to suppress the 
inflammation generated by the meal (174). A 900-kcal AHA step 2 diet-based meal rich in fruit 
and fiber does not cause significant oxidative stress or inflammation, in contrast to the effect of 
an isocaloric fast food meal (360). Postprandial increases in circulating IL-6 levels, but not 
plasma CRP levels, were seen after a high-fat meal in abdominally obese men (361). A 
carbohydrate-rich diet was associated with lower adiponectin concentrations in men (362). 
Weight loss was associated with a decline in CRP levels in many studies, showing that each 1 
kg loss in weight results in a mean decrease in CRP of 0.13 mg/L (363). The mediterranean diet 
has been shown to be inversely associated with the incidence of the MetS in a prospective 
study cohort (364). 
   Smoking is a well recognized health hazard. In addition to its effects on cardiovascular and 
cancer morbidity, it induces central obesity (365) and increases the risk of developing  
hypertension, independently of inflammation (366) and type 2 diabetes (367). 
   Epidemiological studies have shown an association between moderate alcohol consumption 
and reduced risk for the MetS and T2DM. The mechanisms reported to explain this observation 
include improvement of the lipid profile, especially increased levels of HDL cholesterol (368) 
and increased insulin sensitivity (369). This positive effect may be mediated through alcohol-
induced increases in adiponectin (362,370,371), also in women (372).The positive 
cardioprotective effect of moderate alcohol consumption was seen, in particular, in men with the 
MetS (373). 
   The intake of coffee may lower the risk of type 2 diabetes. However, although the explanation 
for this coffee-induced increased insulin sensitivity and type 2 diabetes risk reduction is not 
known (374-376), it may be caused by increased levels of adiponectin, at least in women (377). 
Higher magnesium intake, mainly from whole grain consumption, in young adults was also 
associated with lower risk of MetS (378). On the other hand, elevation in the markers of the iron 
metabolism increased the incidence of the MetS in both sexes (379). Another new lifestyle 
feature is the voluntary restriction of sleep duration. Self-reported sleep duration has decreased, 
while during the same time obesity, MetS and T2DM have increased (380). Both short (<6h) 
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and long (>8h) sleep duration is related to increased risk (381,382). Psychosocial, stressful life 
events (383) and low socioeconomic status (384) also predict the risk for developing the MetS. 
A positive association has been found between serum concentrations of persistent organic 
pollutants and insulin resistance among nondiabetic adults. The expected association between 
obesity and diabetes was absent in people with low concentrations of persistent organic 
pollutants, but association became much stronger along with a higher concentration of 
pollutants (385). 
 
2.5. Treatment and clinical aspects of the metabolic syndrome 
 
Prevention of the MetS and its complications, diabetes and CVD, is an important public health 
goal. Lifestyle modification to reduce obesity, increase physical activity and quit smoking, is 
primary on both the population and individual levels. After the successful DPS (348) and DPP 
(349) studies, population-based programs to prevent diabetes, and MetS at the same time, 
have been launched by the International Diabetes Federation (IDF) (386), and also at national 
level, as in the Finnish implementation program to prevent type 2 diabetes (FIN-D2D) (387). 
Lifestyle modification, especially increased physical activity, is the only known treatment without 
side-effects which affects positively all components of the MetS. This is important, as 
cardiovascular mortality is higher, when more components of the MetS are present (388). 
   If therapeutic lifestyle modification fails, or if the 10-year cardiovascular risk is high, drug 
therapy to modify different components might be required in addition (33).      
   Classically, as described below in Figure 3, antihypertensive drugs (389), such as 
angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers, and lipid-
lowering statins, are required along with lifestyle changes (390,391). Low-dose aspirin is 
needed to prevent MetS-related increase in arterial thrombosis formation (392). 
   The metabolic abnormalities clustering around abdominal obesity should be the main target 
for the drugs used in the treatment of the MetS. The recent discovery of the endocannabinoid-
CB1 receptor system and its impact on the regulation of the energy metabolism represents a 
significant advance (393). Studies with rimonabant, the first CB1 blocker, show that in 
overweight/obese subjects 20 mg/day was associated with clinically meaningful weight loss, a 
reduction in abdominal obesity, and improvements in insulin resistance, lipid profile, and 
glucose metabolism. Overall, LDL cholesterol levels remained unchanged. These positive 
effects may be mediated by increased levels of adiponectin. Rimonabant was generally quite 
well tolerated, but  increase in depression requires special attention (394,395). 
   Inflammation is strongly associated with the features of the MetS, and elevated CRP level is 
one marker of this. Lifestyle therapies will reduce concentrations of CRP and thus mitigate an 
underlying inflammatory state (363). No specific anti-inflammatory drugs are available to treat 
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the proinflammatory state. However, statins are reported to reduce the concentration of CRP 
(396), and patients who have low CRP levels after statin therapy have better clinical outcomes 
than those with higher CRP levels, regardless of the level of LDL cholesterol (397).  
 
 
Figure 3. Treatment of the metabolic syndrome. 
 
  Also, thiazolidinediones (e.q. rosiglitazone and pioglitazone) a class of insulin-sensitizing 
agents currently used in the treatment of diabetic hyperglycemia, are known to lower CRP 
levels and have positive effects on endothelial dysfunction (398). They were believed to be ideal 
candidates for the early treatment of many components associated with the MetS, as they also 
increase adiponectin levels (399); however, recent associations, especially in connection with 
rosiglitazone, with increased cardiological problems have made this class less promising (400). 
Antagonist of TNF-Į, etanercept, has also been found to lower CRP in the MetS (401). The 
strong association between hypoadiponectinemia and metabolic dysfunction provides the 
perfect scenario for adiponectin replacement therapy. Cellular and animal studies have shown 
evidence for the benefit of adiponectin therapy (402). This may include the increase of plasma 
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adiponectin levels by the upregulation of adiponectin receptors, or the development of 
adiponectin receptor agonists (214). Metformin, which have been used more than 50 years, 
may be the safest drug to accompany lifestyle modification in the MetS (355). 
 
2.6. Early life and the metabolic syndrome in  adulthood 
 
The discovery that individuals who develop coronary heart disease grow differently during early 
life has led to the recognition of new developmental models for the disease. In 1995 David 
Barker wrote: “The fetal origins hypothesis states that fetal undernutrition in middle to late 
gestation, which leads to disproportionate fetal growth, programmes later coronary heart 
disease” (403). Barker’s hypothesis is also known as the ”Thrifty phenotype hypothesis”. In 
humans, birth size serves as a marker of the intrauterine environment. Considering that birth 
size is just one snapshot of the trajectory of fetal growth, it is intriguing that long-term health 
outcomes are predicted by the body size of the newborn (404). 
   The association between birth size and cardiovascular morbidity is largely modified by growth 
later in life. The highest risk of coronary disease was found among individuals who were born 
small and became heavier during childhood (405).This association was especially noticable in 
women who crossed from the low centile of weight at birth to the high centile of BMI in 
adulthood (406). Low weight gain during infancy increases the risk for IGT and type 2 diabetes. 
The effect was greater in people who had low birth weight (407). Low BMI at 2 years of age and 
increased BMI from 2 to 11 years of age were also associated with insulin resistance later in life 
(408). Also hypertension (409,410) later in life and its complication, stroke (411), is associated 
with infant and childhood growth. 
   These epidemiological findings identify the phenomena of fetal programming without 
explaining the underlying mechanisms that establish the causal link. Animal models have 
demonstrated that reduction in the availabilty of nutritients during fetal development programs 
the endocrine pancreas and insulin-sensitivive tissues. The molecular mechanisms responsible 
for intrauterine programming of the E-cells remain elusive, but two hypotheses have emerged: 
programming of mitochondrial dysfunction (412) and epigenetic regulation, which means the 
interaction of genes and uterine environment (413). Strong evidence for epigenetic 
programming comes from monozygotic twin studies (414). 
   These theories are problematic with respect to explaining the growing epidemic of obesity and 
MetS in westernized countries, as the relative proportion of underweight newborn children is 
decreasing (415). Obesity at the age of seven is seen to predict the MetS in adulthood 
(416,417), and it is possible that the Ala12 allele of the PPARJ2 gene is associated with high 
weight and ponderal index at birth, and weight gain and high waist circumference in adulthood 
(418). Hypoadiponectinemia, observed even in visceral adiposity in adolescents (419), may 
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partly explain the fact that overweight in childhood (420) and adolescence (421) increases the 
risk of CHD in adulthood. 
 
2.7. Gender differences in the metabolic syndrome, diabetes and cardiovascular disease 
 
In the general population CHD morbidity and mortality vary widely with a distinctive male-
preponderance: a male-female ratio of approximately 2,5 has been found in different countries 
(422). 
   Diabetes abolishes the normal gender-related difference in the risk for CVD. In the 
Framingham Study the risk for acute MI was 150% greater in diabetic than nondiabetic women, 
but only 50% greater in diabetic than nondiabetic men when adjusted for hypertension, 
dyslipidemia and obesity among individuals aged from 50 to 59 years (423). In the Framingham 
study diabetic women were at a similar absolute risk as their men counterparts, at a 2-fold risk 
in comparison to male nondiabetic subjects, and at a 4-fold risk in comparison to female 
nondiabetic subjects for CVD (424). In a Finnish study diabetes-related risk for CHD mortality 
was 4-fold in men and 24-fold in women, and for CHD incidence 3- and 14-fold, respectively 
(425). After adjusting for conventional risk factors the proportion of diabetes-related CHD risk 
remained more unexplained in women than in men (425). In Finnish women the association 
between diabetes and mortality was stronger than that between myocardial infarction and 
mortality, whereas the opposite was true among men (426). Recent data from NHANES show 
that the reduction in mortality rates among diabetic patients during last decades has been 
limited to men (427). 
   Low-grade inflammation, especially increased CRP levels, have been shown to predict CHD 
(428), and development of the MetS and type 2 diabetes in men (429) and women (430,431). In 
the Hoorn study a significant association of hs-CRP with incident DM was observed in men, but 
not in women (432). In Japanese subjects this association was observed in both sexes (433), 
but solely in women in the Mexico City Diabetes Study (434) and in the MONICA/KORA study 
(435). 
   Women have higher levels of adiponectin than men (127). In the Hoorn Study a high level of 
adiponectin was strongly associated with a low risk for IGT and T2DM, especially in women 
(230). Lower plasma adiponectin concentrations characterize women with previous gestational 
diabetes mellitus independently of their prevailing level of insulin sensitivity or degree of obesity, 
and are associated with subclinical inflammation and atherogenic parameters (436). 
   Endogenous sex hormones may, at least in part, explain the gender differences in the risk for 
diabetes in the prediabetic state and CHD. A recent meta-analysis demonstrated that high 
testosterone levels are associated with higher risk for T2DM in women but with lower risk in 
men (437). Low sex hormone-binding globulin is associated with the MetS in women (438). 
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Testosterone replacement therapy has been found to improve insulin resistance, visceral 
adiposity and hypercholesterolemia in hypogonadal men with T2DM (439), and rapid weight 
loss in abdominally obese men with the MetS resulted in a sustained increase in free 
testosterone levels (440). 
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3. AIMS OF THE STUDY 
 
This study was undertaken to investigate the associations of adiponectin and low-grade 
inflammation, measured by hs-CRP and IL-1 Ra, with the metabolic syndrome in a population-
based study. 
 
The specific aims were: 
 
1. To examine the association of IL-1 Ra, hs-CRP and adiponectin with relative weight gain 
between childhood and adulthood.  
 
2. To investigate the relationship between insulin sensitivity with adiponectin and  inflammatory 
markers (hs-CRP and IL-1 Ra) levels.  
 
3. To evaluate the differences and associations between inflammatory markers (hs-CRP and IL-
1 Ra) and adiponectin with the MetS according to the NCEP and IDF definitions.  
 
4. To study the gender difference in the association of the levels of adiponectin, hs-CRP and IL-
1 Ra with the MetS as defined by the IDF and NCEP criteria.  
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4. SUBJECTS AND METHODS 
 
4.1. Subjects 
 
The study population consisted of middle-aged, Caucasian subjects (n=1 294) born in 1942, 
1947,1952, 1957 and 1962 in Pieksämäki, Finland. The gender and age distribution of the study 
population is shown in Figure 4. The gender distribution in different age groups  was not 
statistically significant. The entire age group was recruited from the local population records by 
three separate invitations. No exclusion criteria were applied. Altogether 923 (411 men and 512 
women) of 1 294 subjects (71.3 %) participated in this cross-sectional study in 1997-98. 
   For the statistical analysis we excluded 18 subjects (7 men and 11 women) whose hs-CRP 
concentration was 10.0 mg/L in order to eliminate possible cases of acute infections and other 
occult diseases, leaving a total of 905 subjects. Additional three women were lost from 
statistical analysis because of missing data for the components of the MetS. In Studies III and 
IV analysis was done for 902 participants. In study II analysis was done for 907 subjects, 
because we excluded all the 15 subjects with known diabetes and 1 subject whose hs-CRP 
concentration was > 30.0 mg/L.  
    The study protocol was approved by the Ethics Committee of the Kuopio University Hospital 
and the University of Kuopio. All the participants gave an informed written consent. 
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Figure 4. The whole study population by age group and gender. 
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4.2. Clinical  methods 
 
All the measurements were done by two trained nurses at Pieksämäki. Body mass index (BMI) 
was calculated as weight (kg) divided by height (m) squared. Height and weight were measured 
to the nearest 0.5 cm and 0.1 kg, respectively. Waist was measured at the midpoint between 
the lateral iliac crest and the lowest rib to the nearest 1.0 cm. Blood pressure was measured 
twice with subjects in a sitting position after a 15-minute rest with a mercury 
sphygmomanometer. The latter value was used in statistical analysis. No physical examination 
was done by a physician.  
   All participants filled a standard questionnaire, including questions about smoking habits and 
physical activity. A current smoker was a subject who smoked at least once a day. Physical 
activity was defined as exercise that makes a person sweat at least mildly. Subjects exercising 
more than three times a week for at least 30 minutes per session were defined as physically 
active.  
    Fasting blood samples were drawn after 12 hours of fasting. Plasma was separated by 
centrifugation, and samples frozen immediately at -20˚ C and sended weekly from Pieksämäki 
to Kuopio and stored there at -70˚C until analyses in 2003. 
 
4.3. Assays and calculations 
 
 Insulin was determined by the Phadeseph Insulin Radio-immunoassay (RIA) 100 method 
(Pharmacia Diagnostics AB, Uppsala, Sweden). Glucose concentration was measured by the 
automated colorimetric method (Peridochrom Glucose GOD-PAP, Boehringer, Germany). 
Insulin sensitivity was calculated as follows: QUICKI = 1/(log FPI+ log FPG), where FPI = 
fasting plasma insulin level expressed as mU/l, and FPG = fasting plasma glucose level 
expressed as mg/dL (165). 
    Serum cholesterol and triglycerides were measured at Pieksämäki from fresh serum samples 
with enzymatic colorimeter methods (CHOD-PAP, GPO-PAP, Boehringer Mannheim GmbH, 
Germany). Serum HDL cholesterol was measured using the same methods after the 
precipitation of low-density cholesterol and very-low-density lipoprotein cholesterol by 
phosphotungstic acid and magnesium.  
    Serum adiponectin was determined with an enzyme immunoassay (human Adiponectin 
ELISA Kit, B-Bridge International Inc., Mountains View, CA, USA). Plasma concentration of IL-1 
Ra was measured with high-sensitivity assay kits from R&D Systems (Minneapolis, MN, USA). 
C-reactive protein (CRP) was measured with an Immulite 2000 High Sensitivity CRP assay 
(DPC, Los Angeles, CA, USA). All these adiponectin, IL-1 Ra and hs-CRP measurements were 
done at the same time (2003) in Kuopio University. 
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4.4. Statistical analyses 
 
The results in the studies I, III and IV are expressed as means and standard deviation (SD), 
with 95% confidence intervals (95% CI). Statistical significance between groups was evaluated 
by the chi-square test or  t-test. When the assumptions of parametric tests were violated  
permutation test (Monte Carlo p-value), bootstrap t-test or analysis of variance (ANOVA) were 
used. Confidence intervals for means were obtained by bias-corrected and accelerated 
bootstrapping (5000 replications), because of the skewed distribution of the variables. The 
normality of the variables was tested by using the Shapiro-Wilk W test. Agreement between 
definitions was determined by the kappa statistic (ț) or Jaccard similarity index (Chamberlain's 
positive agreement). The level of agreement is considered to be moderate with ț=0.41 to 0.60, 
substantial with ț=0.61 to 0.80, and very good with ț>0.80 (441). Bootstrap-based multiplicity 
adjustment was applied to correct levels of significance for multiple testing when appropriate 
(IV). 
    Statistical analysis in the Study II was performed (unlike in the other studies) using the SAS 
version 9.1 for Windows (SAS Institute Inc., Cary, NC, USA). The results are shown as means 
and standard deviations (SD), except for variables with a skewed distribution (insulin, 
adiponectin, hs-CRP, IL-1 Ra), which are given as medians and interquartile ranges, unless 
stated differently. The levels of serum plasma adiponectin and inflammatory markers (hs-CRP 
and IL-1 Ra) were logarithmically transformed to obtain a normal distribution. The comparison 
between men and women was performed with Student’s t-test for continuous variables and with 
the chi-square test for categorical variables. Simple and partial Pearson correlations were 
calculated to examine the association of  QUICKI with adiponectin and inflammatory markers 
without adjustment and after adjustment for age, gender, BMI, smoking status, and physical 
activity.The Į level was set at 0.05 for all tests. 
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5. RESULTS 
 
5.1. Characteristics of the study subjects 
 
The basic demographic, clinical and biochemical characteristics of study subjects regarding the 
components of the MetS and adiponectin and pro-inflammatory markers (hs-CRP and IL-1 Ra) 
are shown in Table 3 and Figure 5. 
 
Table 3.  Demographic, clinical and biochemical characteristics of the whole study population. 
 
Variables Men  
(N=411) 
Mean (SD) 
Women 
(N=512) 
Mean (SD) 
P-value 
Demographic    
   Age, years 46 (6) 46 (6)  
   Body mass index, kg/m² 26.7 (3.8) 26.3 (4.9) 0.15 
   Waist, cm 93.8 (10.6) 83.3 (12.2) <0.001 
Clinical    
    Blood pressure, mmHg    
        Systolic 137 (17) 131 (17) <0.001 
        Diastolic 84 (10) 79 (9) <0.001 
Biochemical    
     HDL cholesterol, mmol/l  1.3 (0.3) 1.5 (0.3) <0.001 
     Triglycerides, mmol/l 1.7 (1.3) 1.2 (0.6) <0.001 
     Fp-glucose, mmol/l 5.9 (0.6) 5.6 (0.5) <0.001 
     Fp-insulin, mU/l 10.7 (5.9) 9.8 (6.5) 0.033 
     hs-CRP, pg/ml 1.3 (1.5) 1.5 (1.7) 0.035 
     IL-1 Ra, pg/ml 172 (131) 192 (167) 0.16 
     Adiponectin, ȝg/ml 4.9 (2.7) 7.9 (4.4) <0.001 
HDL = high density lipoprotein, hs-CRP = high-sensitivity C-Reactive Protein 
IL-1 Ra= Interleukin-1 Receptor antagonist. 
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Figure 5. Waist circumference is shown for the entire study population. According to the IDF 
definition of the MetS, waist circumference was normal in 51% of men and 45% of women. 
According to the NCEP criteria, waist circumference was normal in 79% of men and 69 % of 
women. 
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5.2. Associations of adiponectin and pro-inflammatory markers with relative change in 
BMI between childhood and adulthood (Study I)  
 
The study population comprised all those for whom information on weight and height at the age 
of 7 years (the start of primary school) was available from their local health registries. The levels 
of  cytokines were lower in men than in women (Table 4). These data were available for 368 
subjects, who did not differ in their clinical characteristics and laboratory values from subjects 
lacking weight and height data at the age of 7 years. The age group born in 1962 was not 
included in this study (Figure 6). The relative change in BMI  was calculated as adult BMI 
divided by childhood BMI. 
 
 
Year of birth
1942 1947 1952 1957 1962
N
um
be
r o
f s
ub
jec
ts
0
20
40
60
80
100
120
140
160
180 Men
Women
 
 
 Figure 6. The population (N=368) in Study I by age group and gender. 
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Table 4. Demographic data in childhood and adulthood and clinical and biochemical 
characteristics of the subjects in Study I in adulthood. 
 
Characteristics Men 
N=176 
Mean (SD) 
Women 
N=192 
Mean (SD) 
P-value 
Demographic    
  At 7 years    
      Height, cm 122 (5) 121 (5) NS 
      Weight, kg 23 (4) 23 (4) 0.22 
      Body mass index, kg/m2     15.4 (1.3)     15.4 (1.7) 0.91 
   Adulthood    
      Age, years 46 (4) 46 (5) 0.11 
      Height, cm 177 (6) 163 (6) <0.001 
      Weight, kg 82 (12) 70 (13) <0.001 
      Body mass index, kg/m2   26.3 (3.4)    26.2 (4.9) 0.81 
Clinical    
   Blood pressure, mmHg 
      Systolic  
      Diastolic 
 
135 (16) 
83 (10) 
 
130 (17) 
79 (9) 
 
0.002 
<0.001 
Biochemical    
   Total cholesterol, mmol/l 5.9 (1.0) 5.6 (1.0) 0.009 
   HDL cholesterol, mmol/l  1.3 (0.3) 1.5 (0.3) <0.001 
   Total triglycerides, mmol/l 1.6 (0.9) 1.3 (0.8) 0.002 
   Fasting plasma glucose, mmol/l 6.0 (1.0)  5.7 (1.0) <0.001 
   Adiponectin,  μg/ml 4.6(2.2) 8.0(4.8) <0.001 
   hs-CRP, pg/ml 1.4(2.4) 2.0(2.8)    0.03 
   IL-1 Ra, pg/ml 166(97) 209(223)  0.02 
NS = non-significant; HDL = high-density lipoprotein. 
  
Figures 7-8 show the significant positive relationship between the inflammatory markers (hs-
CRP and IL-1 Ra) at adulthood and the relative change in BMI from childhood to adulthood. 
Figure 9 shows the significant inverse relationship between adiponectin measured at adulthood 
and the relative change in BMI from childhood to adulthood. In both sexes the strongest 
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correlation was found between the relative change in BMI from childhood to adulthood and IL-1 
Ra: for women (r= 0.64 (95% CI: 0.55 to 0.72)) and for men (r= 0.27 (95% CI: 0.12 to 0.40)). 
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Figure 7. Relationship between IL-1 Ra levels at adulthood and the relative change of BMI 
between childhood and adulthood in males and females. 
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Figure 8. Relationship between hs-CRP levels at adulthood and the relative change of BMI 
between childhood and adulthood in males and females. 
58
  
Relative change of BMI from childhood to adulthood
1,0 1,5 2,0 2,5 3,0
Ad
ip
o
ne
ct
in
 
(P g
/m
l) a
t a
du
lth
o
od
0,1
1
10
Male
r = -0.13 (95% CI: -0.27 to -0.01)
Relative change of BMI from childhood to adulthood
1,0 1,5 2,0 2,5 3,0
Ad
ip
on
e
ct
in
 
(P g
/m
l) a
t a
du
lth
o
od
0,1
1
10
Female
r = -0.29 (95% CI: -0.42 to -0.16)
20
30
20
30
 
 
 
Figure 9. Relationship between adiponectin levels at adulthood and the relative change of BMI 
between childhood and adulthood in males and females. 
 
5.3. Associations of adiponectin, C-reactive protein and interleukin-1 receptor antagonist 
with insulin sensitivity in a population-based cohort (Study II) 
 
Insulin sensitivity in this study was measured by QUICKI-index.  About 50% of subjects were 
physically active, and 34% of men and 22 % of women were current smokers. The median 
adiponectin concentration was lower in men than in women (4.2 vs. 6.9 μg/ml, p< 0.001). Levels 
of hs-CRP were higher in women than in men (0.9 vs.0.7 pg/ml, p=0.040). There was no 
statistically significant difference between the sexes in the levels of IL-1 Ra (men vs. women, 
141 vs. 149 pg/ml, p= 0.071). The QUICKI index was higher in women than in men (0.340 vs. 
0.334, p<0.001) (Table 5). 
   The Pearson correlation between QUICKI and adiponectin level was 0.334 (95% CÍ, 0.275 to 
0.392) and partial correlation adjusted for gender, age, BMI, smoking status and physical 
activity was 0.247 (95% CI, 0.185 to 0.308). IL-1 Ra and CRP correlated inversely with QUICKI. 
The correlation between QUICKI and IL-1 Ra, adjusted for gender, BMI, smoking status, 
physical activity and age was statistically significant (Table 6). 
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Table 5. Clinical and laboratory characteristics of the Study II population. 
 
Variables Males 
N=400 
Females 
N=507 
P-value 
Age, years 47 ± 6 46 ± 6 0.58 
Current smokers (%) 34 22 <0.001 
Physically active (%) 46 54 0.43 
BMI (kg/m2) 26.6 ± 3.7 26.3 ± 5.0 0.27 
Waist (cm) 93.6 ± 10.2 83.4 ± 12.3 <0.001 
Quicki 0.334 ± 0.023 0.340 ± 0.022 <0.001 
Fp-glucose (mmol/l) 6.0 ± 0.9 5.7 ± 0.6 <0.001 
Fp-insulin (mU/l) 8.9 (7.0-12.3) 8.7(6.8-11.1) 0.11 
Adiponectin (ug/ml) 4.2(3.0-6.0) 6.9(4.8-9.7) <0.001 
hs-CRP (pg/ml) 0.7(0.3-1.8) 0.9(0.4-2.2) 0.040 
IL1–Ra (pg/ml) 141(104-202) 149(105-219) 0.071 
Data are mean ± SD, medians (interquartile ranges), or percent. BMI=body mass index, 
hs-CRP = high-sensitivity C-reactive protein; IL-1 Ra= interleukin 1 receptor antagonist, 
 
 
Table 6. Association of insulin sensitivity, measured by QUICKI, with adiponectin, high-
sensitivity C-reactive protein (hs-CRP) and interleukin 1 receptor antagonist (IL-1 Ra) levels. 
 
 
$
 Data logarithmically transformed.§ Adjusted for sex, BMI, smoking status, physical activity, and 
age. 
 
Inflammation cytokines Quantitative insulin sensitivity check index (QUICKI) 
 Pearson correlation  Partial correlation§ 
 
r (95 % CI)  r (95 % CI) 
Adiponectin$ (ug/ml) -0.334 ( 0.275 to  0.392)  -0.247 ( 0.185 to 0.308) 
hsCRP$ (pg/ml) -0.241 (-0.302 to -0.178)  -0.004 (-0.070 to 0.062) 
IL1–Ra$ (pg/ml) -0.385 (-0.440 to -0.328)  -0.178 (-0.240 to -0.113) 
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Figure 10. A scatter-plot between insulin sensitivity, measured by QUICKI, and log-transformed 
adiponectin, hs-CRP), and IL-1 Ra levels. Pearson and partial Pearson correlation coefficients 
(adjusted for age, gender, body mass index, smoking status and physical activity) and 
regression line are shown.  
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The correlation between QUICKI and adiponectin, CRP and IL-1 Ra and the partial correlation 
(adjusted for age, gender, BMI, smoking status and physical activity) are shown in Figure 10 for 
both sexes. The gender difference was statistically significant only for IL-1 Ra (p=0.017). In 
women the correlation of QUICKI with IL-1 Ra was -0.500 and partial correlation -0.279, and in 
men the corresponding correlations were -0.348 and -0.142.  
 
5.4. The associations of CRP, IL-1 Ra and adiponectin with the metabolic  
syndrome defined by the NCEP and the IDF criteria (Study III) 
 
Among the 923 participants, the prevalence of the MetS according to the IDF definition was 
38% in men and 34% in women. According to the NCEP criteria the corresponding numbers 
were 34% in men, and 27% in women. In women the agreement (ț) between the IDF and NCEP 
criteria was 0.75 (95% Cl 0.68 to 0.81) and in men 0.60 (95% Cl 0.52 to 0.68). 
    Insulin sensitivity index measured by QUICKI was significantly higher in both men and 
women without the MetS than with the MetS according to both definitions (the IDF criteria: 
0.35±0.18 vs. 0.32±0.02, p<0.001; the NCEP criteria: 0.35±0.02 vs. 0.32±0.02, p<0.001). 
   When the MetS was present according to both IDF and NCEP definitions, waist and 
triglyceride levels were significantly higher and HDL cholesterol lower in both men and women 
compared to those who had the MetS according to the IDF but not NCEP criteria, or the MetS 
according to the NCEP but not IDF criteria (Table 7).  
   In men the mean hs-CRP level was 1.00 pg/ml in those having the MetS only according to the 
NCEP definition, 1.52 pg/ml in those having the MetS only according to the IDF definition, and 
1.73 pg/ml in those having the MetS according to both definitions (IDF and NCEP) (p=0.033 
between groups and linearity 0.020). In women the corresponding mean hs-CRP levels were 
0.81, 1.45 and 2.62 pg/ml (p<0.001 between the groups, linearity 0.010). The corresponding 
levels of adiponectin and IL-1 Ra for both sexes are also shown in Table 8.  
   Figure 11 shows the correlation of adiponectin, hs-CRP and IL-1 Ra with the number of 
components of the MetS present (0-1, 2-3, 4-5) according to the IDF and the NCEP criteria for 
both men and women (p for linearity < 0.001 in all definitions). 
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 Figure 11. Relationship between adiponectin, hs-CRP, IL-1 RA and the number of components 
of the metabolic syndrome according to the IDF and NCEP criteria (mean and 95% confidence 
intervals obtained by bias-corrected and accelerated bootstrapping).  
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 5.5. Gender differences in CRP , IL-1 Ra and adiponectin levels in the metabolic 
syndrome defined by the NCEP and the IDF definitions (Study IV) 
 
Waist circumference, blood pressure, triglyceride and glucose levels were higher and HDL 
cholesterol concentrations lower in men than in women (p<0.001). Mean adiponectin (7.9(4.4) 
vs. 4.9(2.7) ȝg/ml, p < 0.001) and mean hs-CRP levels were higher in women than in men 
(1.5(1.7) vs. 1.3(1.5) mg/L, p=0.035), but no gender  difference was found in IL-1 Ra levels. No 
gender difference was found in the use of drugs for treatment of hypertension and dyslipidemia. 
The prevalences of the MetS were the same as in Study III. Adiponectin levels were significantly 
lower (p<0.001) and hs-CRP and IL-1 Ra concentrations higher (p<0.001) in subjects with the 
MetS compared to subjects without the MetS. 
   In subjects with the MetS defined by the IDF criteria the gender difference in the levels of hs-
CRP (higher in women) was 0.65 mg/L [(95% CI, 0.23 to 1.06), p<0.001] and in the levels of IL-
1 Ra 67 pg/ml [(95% CI, 21 to 113), p=0.0028]. Similar gender differences were observed in 
subjects with the MetS according to the NCEP criteria (the gender difference in hs-CRP levels 
was 0.92 mg/L [(95% CI 0.47 to 1.41), p<0.001] and in IL-1 Ra levels 83 pg/ml [(95% CI 32 to 
135), p=0.0016]). In subjects without the MetS, hs-CRP and IL-1 Ra levels did not differ 
between the sexes (Table 9). 
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6. DISCUSSION 
 
6.1. Study population and design 
 
The study population consisted of middle aged (mean age about 46 years) Caucasian subjects 
from the city of Pieksämäki, eastern Finland. Entire age groups, born in 1942, 1947, 1952, 1957 
and 1962, were recruited from the local comprehensive population data records by three 
separate invitations. No exclusion criteria were applied. Altogether 923 of 1294 subjects 
(71.3%) participated in this  cross-sectional study conducted in 1997-98 at Pieksämäki health 
center.  
   This is a representative population-based age-cohort study. The gender distribution did not 
differ between the age groups. The strength of this study is that the number of male participants 
(44.6%) was high compared to many other population-based studies (52). The prevalence of 
the MetS in the study population (IDF men 38%,women 34% and NCEP men 34% and women 
27%) was about the same as in the Oulu project Elucidating the Risk of Atherosclerosis study, 
which is a population-based study with participants randomly selected from Finnish national 
population register (220). In that study population (mean age about 50 years) the prevalence of 
the MetS was, on the IDF definition, 37.6% and on the NCEP definition 29.8% of all study 
subjects.  
   Because of the rather low mean age of our study population, there were only few cases of 
diagnosed CHD (4/0.4%) and DM (15/1.6%). Of the total population 43 (4.7%) of men and 41 
(4.4%) of women were on antihypertensive medication, and 14 (1.5%) and 6 (0.7%) on lipid 
lowering medication. 
   Due to the nature of the study there is no data about the missing 28.7% of the study 
population who did not attend despite three invitations. The missing subjects were, anyhow, 
evenly distributed  to all age groups. It is unlikely that this will effect the study results. 
 
6.2. Study methods 
 
The adiponectin, hs-CRP and IL-1 Ra analyses were determined at the scientific laboratory of 
Kuopio University. To minimize the inter-assay variations all the analysis of cytokines and 
adiponectin were performed at the same time in 2003. Fresh plasma samples were immediately 
frozen to –20qC and stored at –70qC after transportation to the central laboratory. As far as 
known, the analyses are reliably done after at least 3-5 years storage in –70 qC (442). One 
limitation of our study may be that we measured total adiponectin and not the high molecular 
weight (HMW) multimer of adiponectin, which has been shown to be a better marker for the 
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MetS than total adiponectin (443), especially in early diagnosis of insulin resistance in 
metabolically obese, normal weight subjects (444). 
   In Studies III and IV 18 subjects (7 men and 11 women)  were exluded whose hs-CRP 
concentrations were >10,0 mg/L in order to eliminate possible cases of acute infections and 
other occult diseases. In the insulin resistance study (Study II) 15 (1.6%) persons were 
excluded from all statistical analyses due to known diabetes and one person with CRP >30 
mg/L, as treatment for diabetes and acute infections could effect our results. However, when 
these subjects were included in the statistical analysis, the results remained essentially the 
same. 
   A limitation of these studies is the cross-sectional design, which does not give answers 
regarding the exact predictive values of adiponectin and cytokines for diabetes and 
cardiovascular disease, which are the main future complications of the MetS. 
 
6.3. Associations of cytokines and adiponectin with growth between childhood and 
adulthood  
 
 
The novel finding in this study is an association between the relative change in BMI from 
childhood to adulthood and levels of adiponectin and markers of a low-grade inflammation 
measured in adulthood. This might mean that decreased levels of adiponectin and elevated 
levels of IL-1 Ra and hs-CRP are  indicators of relative BMI change. The association was 
particularly strong among women, but it was also present in men. This may suggest that in 
females the growth pattern, i.e., fat distribution, is different from that in males. The gender 
difference is, however, unclear, as in one study intra-abdominal fat tended to be higher in men 
than in women (445), while in another women and men had similar amounts of liver and intra-
abdominal fat, but women had more subcutaneous fat (446). In general women have a higher 
percentage of body fat than men, and markers of inflammation correlate strongly with measures 
of adiposity (447). 
    The elevated levels of the low-grade inflammatory markers used (IL-1 Ra and hs-CRP) and 
low levels of adiponectin reflected BMI gain retrospectively. IL-1 Ra had the strongest 
correlations with relative weight change. The level of IL-1 Ra has been shown to be markedly 
and reversibly elevated in human obesity and predicted by lean body mass and insulin levels 
(274). IL-1 Ra has also been shown to be the most sensitive marker of cytokine response in the 
prediabetic state in the offspring of type 2 diabetic patients (277). Later on the levels of IL-1 Ra 
decrease as type 2 diabetes develops (278). This might indicate that it protects cells from being 
overloaded by glucose uptake in the diabetic state. 
   Levels of adiponectin are decreased in obesity. Inflammation and the influx of fat into the cells 
associated with obesity could explain this observation by inhibiting adiponectin expression 
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(448). These study results support the hypothesis that adiponectin may be the link between 
over nutrition, weight gain, insulin resistance and cardiovascular disease (126, 228). The recent 
finding that obesity at the age of 18 years increased lifetime risk for diabetes (449) may reflect 
the effect over many years of lower levels of adiponectin and higher levels of cytokines. In 
agreement with this notion a Swedish 6-year follow-up study of 2 821 non-diabetic healthy men 
demonstrated a significant correlation between positive inflammation-sensitive plasma proteins 
(fibrinogen, orosomucoid, Į1-antitrypsin, haptoglobin and ceruloplasmin) and weight gain (450). 
Therefore, the inflammatory process, possibly genetically determined, could be the driving force 
for weight change from childhood to adulthood, and not just a marker of current obesity. 
However, a prospective study, with an admittedly short follow-up period (2-3 years), in Pima 
Indians failed to demonstrate an association between hypoadiponectinemia and weight gain 
(451). 
   A limitation of this study is cross-sectional and retrospective design. For this reason we used 
the relative change in BMI from childhood to adulthood. Prospective studies from childhood to 
adulthood are needed to verify this finding and to show whether the inflammation comes first 
and, if so, whether it predicts future fat mass.  
   It can be concluded that elevated levels of inflammatory markers IL-1Ra and hs-CRP and 
decreased levels of adiponectin are related to relative  change in BMI from childhood to 
adulthood in both females and males.  
 
6.4. Associations of adiponectin, hs-CRP and IL-1 Ra with insulin sensitivity  
 
 
The finding of this population-based study (n=923) was that QUICKI correlated significantly with 
adiponectin and IL-1 Ra levels. However, the correlation between QUICKI and hs-CRP was not 
statistically significant after adjustment for age, gender, BMI, smoking status and physical 
activity. Therefore, it is possible that inflammation is more a consequence than a cause of 
obesity and insulin resistance.  
   This data agrees with previous results indicating that a low level of adiponectin is associated 
with decreased insulin sensitivity and may lead to type 2 diabetes (229). The new finding of the 
present study was that the negative correlation between insulin sensitivity and IL-1 Ra remained 
significant after adjustment for gender, BMI, smoking, age and physical activity. The members 
of the IL-1 cytokine superfamily, IL-1 Į and IL-1 ȕ, are strong inducers of inflammation (270). 
Previous studies also show that insulin resistance may precede the elevation of CRP levels in 
the development of obesity and the metabolic syndrome. Similarly to these findings,  in one 
study hs-CRP levels were not significantly associated with insulin sensitivity, but CRP was 
related to adiposity in a study of 10-to 16-year-old children (452). In contrast, in young people 
hypoadiponectinemia has been shown to correlate independently with insulin resistance and 
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visceral obesity (419). Similar strong correlations of adiponectin with insulin sensitivity and CRP 
with adiposity have been demonstrated in studies of adult obese and non-obese people with 
and without disorders of glucose metabolism (453).  
   In this study, the association between QUICKI and hs-CRP was similar in both sexes, but it 
was not as strong as the association between QUICKI and IL-1 Ra. The correlation between 
QUICKI and hs-CRP was not statistically significant after adjustment for confounding factors. 
Generally, hs-CRP is considered to be more a risk factor for coronary heart disease than for 
insulin resistance (248,249). 
   Correlations of adiponectin and CRP with QUICKI were very similar in both sexes. The 
strongest correlation was observed between insulin sensitivity and IL-1 Ra, and this was 
observed especially in women (r=-0.500 Pearson and -0.279 partial correlation). It is not clear 
why there is a gender difference between IL-1 Ra and QUICKI. This may be a consequence of 
differential fat distribution or hormonal differences between the sexes.  
   The other anti-inflammatory markers, especially IL-10, have high correlations with metabolic 
parameters. Previous studies have shown that IL-10 level is elevated in obese women without 
the metabolic syndrome, and that IL-10 level is low in women who have the metabolic syndrome 
or type 2 diabetes (454). A positive correlation of IL-10 level and insulin sensitivity has recently 
been demonstrated in young healthy individuals (455). In the study of the offspring of type 2 
diabetic subjects the level of IL-1 Ra was the most sensitive marker of cytokine response in the 
prediabetic state (277). In that study, the level of IL-1 ȕ was increased in the normal glucose 
tolerance group, whereas it was decreased in the impaired glucose tolerance (IGT) group. 
Eizirik et al. (456) have shown that 10- to 100-fold excess of IL-1 Ra over IL-1 ȕ suffices to 
block the effects of IL-1 ȕ on pancreatic islets. In the above-mentioned study (277) the ratio of 
IL-1 Ra to IL-1 ȕ was found to be >100-fold higher in the IGT group, indicating decreased 
biological activity of IL-1 ȕ. Therefore, it is unlikely that IL-1 ȕ would mediate ȕ-cell failure during 
the progression from IGT to type 2 diabetes. 
    All the statistical analyses in this study were adjusted for smoking status and physical activity. 
Smoking generates systemic inflammation, and thus proinflammatory cytokines might be 
elevated (457). Regular exercise more than three times a week has an anti-inflammatory effect. 
During exercise IL-6 is produced by muscle fibers, and it inhibits the production of 
proinflammatory cytokines, especially tumor necrosis factor (TNF) alpha (356).  
    This study showed that insulin sensitivity, measured by the QUICKI index, and its correlations 
with adiponectin and inflammatory markers corroborate existing evidence that a low adiponectin 
level and low-grade inflammation are associated with insulin resistance.  
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6.5. Hypoadiponectinemia and pro-inflammation in the metabolic syndrome  
 
This study shows that proinflammatory cytokines and adiponectin are associated with  the 
MetS. Cytokine levels were higher and adiponectin levels lower in subjects who had the MetS 
according to both definitions (IDF, NCEP) compared to subjects who had the MetS according to 
only one definition. The only-IDF definition group of the MetS had higher levels of hs-CRP and 
IL-1Ra compared to the group with only-NCEP definition, probably due to abdominal obesity as 
the central criterion for the syndrome. A similar stronger relationship with the IDF compared to 
the NCEP definition was found in a Chinese population with hs-CRP (458). Subjects with the 
MetS according to only the NCEP criteria had quite normal levels of adiponectin and 
inflammatory markers, which may indicate that these subjects are not at such a high risk for 
CVD and/or diabetes. On the other hand the levels of triglycerides were higher and HDL-
cholesterol tended to be lower in this NCEP-only population. In a recent study a similar risk for 
CVD and diabetes was observed in subjects having the MetS according to the IDF, NCEP and 
WHO definitions (56).  
   The current study also confirmed that levels of adiponectin, hs-CRP and IL-1 Ra were 
similarly and linearly correlated with the number of components of the MetS according to the 
IDF and NCEP definitions in both sexes. Similar results have been reported previously with 
respect to the levels of hs-CRP (254,459) and adiponectin (220,460,461) in different 
populations. Despite the fact that hs-CRP and adiponectin have been found to be highly 
correlated with the components of the MetS, it is not yet recommended that they could be 
added to the definition criteria (53). Hs-CRP values are different in different ethnic groups, and 
adiponectin is different between the sexes and also more difficult to measure than the other 
accepted values. In the Finnish Diabetes Prevention Study hs-CRP was the best immunological 
predictor for the progression from impaired glucose tolerance to overt type 2 diabetes (357). 
Our findings show that according to any of the definitions of the MetS, conventional 
cardiovascular risk factors, insulin resistance measured by QUICKI, low adiponectin and high 
levels proinflammatory markers cluster in the same individuals. 
   The prevalence of the MetS was 38 % in men and 34% in women according to the IDF 
definition, and 34% and 27%, respectively, according to the NCEP definition. Our results agree 
with previous results from Finland (220). On the other hand, the level of agreement between 
both definitions was better in women. In large part both definitions of the MetS identified the 
same high-risk individuals, but the IDF definition more reliably identified individuals with more 
unfavourable proinflammatory parameters than did the NCEP definition.  
   In this study it was possible to compare the correlations of IL-1 Ra with hs-CRP and 
adiponectin in the same study population. The new finding was that IL-Ra showed a similar 
correlation to those of hs-CRP and adiponectin with the MetS.  
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    It can be concluded  that decreased levels of adiponectin and increased levels of hs-CRP 
and IL-1 Ra possibly reflect the same phenomenon, and correlate linearly with the number of 
components of the MetS according to both the IDF and NCEP definitions. The levels of 
inflammatory markers (hs-CRP and IL-1 Ra) are higher among patients with the MetS defined 
by only the IDF criteria compared to those defined by only the NCEP criteria.  
 
6.6. Gender differences in hs-CRP, IL-1 Ra and adiponectin levels in the metabolic 
syndrome  
 
 
This study showed that the levels of proinflammatory markers, hs-CRP and IL-1 Ra, were 
significantly higher among women with the MetS compared to men with the MetS, 
independently of the definition used (NCEP, IDF). In contrast, no gender difference in these 
markers between men and women was observed in subjects without the MetS. If it is taken into 
account that obesity and the MetS are strongly related, our results are in line with earlier studies 
showing a stronger association between obesity and hs-CRP in women than in men. This could 
be related to the higher percentage of body fat in women (446,462). A recent finding in Finland 
shows that in women the waist had increased by 2.7 cm over the past 10 years and by only 1.0 
cm in men. Waist circumference increased more than BMI among women, especially 
unemployed women (463). The increasing  waistlines may be involved in increasing T2DM 
numbers among women, because girls are also "intrinsically" more insulin-resistant than boys. It 
was found that girls had 15-25% higher concentrations of cord insulin compared with boys, 
independent of many confounders (464). Is this genetic or epigenetic and what is the role of 
hormones? Although the answers are unknown, these questions have given rise to the "sex 
insulin hypothesis" (465). Insulin-resistant diabetes is common in Turner syndrome (monosomy 
X) (466) and in Klinifelter syndrome/variants (polysomy X) (467). Hormones complicate matters 
further; women are more insulin resistant during their prepubertal and postmenopausal years, 
whereas men seem to be more insulin-resistant during their reproductive years (468). 
   Hypoadiponectinemia is an early marker of this process and reflects the interaction of the 
adiponectin gene and environmental factors related to obesity, insulin resistance and the MetS 
(214). Decreased synthesis of adiponectin has been assumed to lead to dysregulation of the 
mechanisms that inhibit the production of pro-inflammatory cytokines (448). Recent data show 
that the reduction in mortality rates among diabetic patients has been limited to men (427). The 
low-grade inflammation in women with the MetS shown in our study could be one explanation 
why prediabetic women tend to have a more atherogenic risk profile than men years before the 
diagnosis of diabetes (469). This may also explain, at least in part, why the MetS is a stronger 
predictor of cardiovascular disease in women (470) than in men.  
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    It is possible to conclude that women with the MetS had higher levels of hs-CRP and IL-1 Ra 
compared to men. These observed gender-differences in cytokines with long lasting 
inflammatory process may explain why type 2 diabetes is associated with relatively higher 
cardiovascular mortality in women than in men.  
 
6.7. Implications for clinical practice and research 
 
Despite recent criticism of the diagnosis of the MetS, there is no question that risk factors for 
CVD cluster together. So far, no common clearly accepted etiology for the various components 
have been found. The question  is whether this ever-increasing cluster of features conceals a 
distinctive clinical entity and whether it helps to identify people who clearly are at  increased risk 
for CVD and T2DM. 
   However, the identification of subjects, as early as possible, with a high risk for CVD and 
T2DM is of great importance. Tools for identification in clinical practice are easily available and 
they are not expensive. We have a rather well-tested lifestyle modification, which should be 
started as early as possible among patients with the MetS. The prevention of childhood obesity 
epidemics now is of great importance for the near future. In the search for a common etiology of 
the MetS, T2DM and CVD ("common soil hypothesis") the new findings about the active role of 
adipose tissue via adipocytokines and chronic inflammation are emerging as at the core of this 
problem. These studies showed in a population-based level that decreased levels of 
adiponectin and increased levels of markers of chronic inflammation (hs-CRP and IL-1 Ra) 
correlate linearly with the number of components defined by the IDF or the NCEP criteria. What 
is the direction of causality? There is experimental evidence that inflammatory mediators alone 
can trigger insulin resistance in cells, experimental models and humans in the absence of other 
triggering factors, such as obesity (57). This suggests that inflammation is proximal to metabolic 
deterioration and may lead to diabetes. This question cannot, however, be answered in this 
study design, but the prevention of at least a relative change in BMI to higher levels during 
growth is desirable. The results tend support the view that when an obese child reduces his or 
her relative weight to become a non-obese adult, this may protect against the MetS and its 
complications (417). 
   Diabetes as a potentially preventable complication of the MetS is relatively more dangerous 
for women than for men. The recent data show that the reduction in mortality rates among 
diabetic patients has been limited to men. Significantly higher levels of cytokines among women 
with MetS compared to men found in this study could be one explanation why prediabetic 
women have a more atherogenic risk profile than men years before the diagnosis of diabetes. In 
contrast, no gender difference in the cytokines between men and women were observed in 
subjects without the MetS. This long-lasting inflammatory stress may in part explain why type 2 
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diabetes is associated with relatively higher cardiovascular mortality in women and thus lifestyle 
modifications should be started very early among women with the MetS. This large, partly 
unexplained excess risk for CVD in women with type 2 diabetes needs further prospective 
research. 
   For everyday clinical purposes the measurement of IL-1 Ra and adiponectin are not at 
present recommended despite the fact that they are good markers for the MetS. Maybe the use 
of hs-CRP as CHD risk estimate is the most useful among  subjects at intermediate risk (471, 
472). A better understanding of the genes involved in the interplay between the environment 
and the human body in terms of increased waist size and cytokines will help to identify the right 
candidates for preventive therapies, maybe the use of IL-1 Ra for prevention of T2DM is 
possible. Adiponectin replacement therapy or the enhancing  adiponectin action through 
modulation of expression and/or function of adiponectin receptors may be a novel and 
promising therapeutic strategy for the Mets and T2DM  in the future (214).  
 
7. SUMMARY  
 
This study was done to evaluate the associations and meanings of adiponectin and low-grade 
inflammation (measured by hs-CRP and IL-1 Ra) with the MetS in a community-based  age-
cohorts. Five different whole age groups with the mean age of 46 years living in the same 
geographical area were included. These cross-sectional  studies were done during 1997-1998 
and  923 of 1 294 (71.3%) individuals participated. The prevalence of the MetS according to the 
IDF definition was in men 38% and in women 34%. The corresponding figures according to the 
NCEP definition were 34% and 27%. 
   The study showed an association between the relative change in BMI from childhood to 
adulthood and the levels of adiponectin and markers of a low-grade inflammation. This suggests 
that low levels of adiponectin and elevated levels of IL-1 Ra and hs-CRP could be  indicators of 
relative weight gain. The association was particularly strong among women. IL-1 Ra had the 
strongest correlations with relative BMI change. Inflammation associated with obesity could 
explain this observation by inhibiting adiponectin expression. These results support the 
hypothesis that adiponectin may be the link between overnutrition, weight gain, insulin 
resistance and cardiovascular disease. 
   Insulin sensitivity correlated significantly with adiponectin and IL-1 Ra levels, independently of 
confounding factors. Insulin sensitivity did not correlate with hs-CRP after adjustment for age, 
gender, BMI, smoking status and physical activity. The correlations of adiponectin and CRP with 
insulin sensitivity were similar in both sexes. The strongest correlation was observed between 
insulin sensitivity and IL-1 Ra, and this was observed especially in women.  
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   Levels of adiponectin, hs-CRP and IL- 1 Ra were similarly and linearly correlated with number 
of  the components of the MetS according to the IDF and NCEP definitions in both sexes. These 
cytokines and adiponectin are likely to be central components of the MetS. Cytokine levels were 
higher and adiponectin levels lower in subjects who had the MetS on both definitions (IDF, 
NCEP) compared to subjects who had the MetS on only one definition. Both definitions of the 
MetS largely identified the same high risk individuals.  
   The levels of proinflammatory markers, hs-CRP and IL-1 Ra, were significantly higher among 
women with the MetS compared to men with the MetS, independently of the definition used 
(NCEP, IDF). No gender difference in these markers  was observed in subjects without the 
MetS. The relatively greater decrease in adiponectin level in women with the MetS could induce 
more pro-inflammation in women than in men. The low-grade inflammation in women with the 
MetS could  explain why prediabetic women tend to have a more atherogenic risk profile than 
men years before the diagnosis of diabetes.  
In conclusion, the MetS is associated with hypoadiponectinemia and low-grade inflammation. 
An association in this study was found between relative change in BMI between childhood and 
adulthood, insulin sensitivity, the number of components of the MetS and especially in female 
gender. 
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